EFFECT OF GROWTH HORMONE WAS MODULATED BY HYALURONAN AMIDE DERIVATIVE ON HUMAN OSTEOARTHRITIC CHONDROCYTES by Paolella, Francesca
   
 Università degli Studi di Ferrara
 
 
Table of content 
 
Chapter 1   Osteoarthritis ............................................................................................ 1 
1.1. Pathology ............................................................................................................ 1 
1.2. Classification ....................................................................................................... 4 
1.3. Epidemiology ...................................................................................................... 6 
1.4. Risk factors ......................................................................................................... 7 
1.5. Sintomatology ..................................................................................................... 9 
1.6. Physiological modification of the OA joints ..................................................... 10 
1.6.1. Articular cartilage ....................................................................................... 10 
1.6.2. Subchondral bone ....................................................................................... 16 
1.6.3. Synovial membrane .................................................................................... 17 
1.7.  Molecules involved in OA pathophysiology ................................................... 19 
1.7.1. Interleukin-1 (IL-1) .................................................................................... 19 
1.7.2. Interleukin-6 (IL-6) .................................................................................... 20 
1.7.3 Tumor necrosis factor-  (TNF- ) ............................................................... 20 
1.7.4 Prostaglandin E2 (PGE2) ............................................................................ 21 
1.7.5 Fibroblast growth factor (FGF-2) ................................................................ 21 
1.7.6 Insulin-like growth factor (IGF) .................................................................. 22 
1.7.7 Hypoxia inducible factor (HIF) ................................................................... 22 
Chapter 2 Therapeutic treatments for OA.............................................................. 24 
2.1 Non-pharmacological therapy of osteoarthritis .................................................. 25 
2.2 Pharmachological treatments of osteoarthritis ................................................... 28 
2.3 Differents agents ................................................................................................ 32 
2.4 Surgery ............................................................................................................... 32 
Chapter 3  Hyaluronic acid (hyaluronan) ................................................................. 34 
3.1 Biochemistry of hyaluronan ............................................................................... 35 
3.2 HA receptors ...................................................................................................... 36 
3.3 Mechanism of action .......................................................................................... 37 
3.3.1 Condroprotective effects. ............................................................................ 38 
3.3.2 Effects of hyaluronan on the extracellular matrix. ...................................... 38 
3.4 Viscosupplementation ........................................................................................ 39 
3.5 HYADD®4-G .................................................................................................... 40 
Chapter 4  Growth hormone  .................................................................................... 43 
4.1 Physiologic Effects of Growth Hormone ........................................................... 45 
4.2 Secretion and regulation of Growth Hormone ................................................... 47 
4.3 The growth hormone receptor and signal transduction ...................................... 48 
4.4 Negative regulator of GH: Suppressor of Cytokine Signalling-2 (SOCS2) ...... 51 
4.5 GH and signalling molecules in normal and OA cartilage ................................ 53 
4.6 GH in OA treatment ........................................................................................... 56 
Chapter 5   Aim ........................................................................................................ 58 
Chapter 6  Materials and Methods ........................................................................... 60 
6.1 Patient characteristics ......................................................................................... 60 
6.2 Immunoistochemical analysis ............................................................................ 62 
6.3 Cellular culture ................................................................................................... 63 
        6.3.1  Chondrocytes isolation ........................................................................... 63 
        6.3.2 Synoviocytes isolation ............................................................................ 64 
6.4 Experimental culture conditions ........................................................................ 64 
6.5 Cellular morphology .......................................................................................... 65 
6.6 Cellular viability................................................................................................65 
6.7 Cellular metabolic activity ................................................................................. 66 
6.8 Cellular migration .............................................................................................. 67 
6.9. Immunocychemical analysis ............................................................................. 67 
6.10 Molecular biology analysis ............................................................ 68 
       ..............68 
       6.10.2 Reverse transcription ........................................................................ 68 
       6.10.3 Real-Time PCR ...................................................................................... 69 
6.11. Soluble factors analysis  ............................................................................... 71 
       6.11.1 Multiplex system .................................................................................... 71 
       6.11.2 Test ELISA : Enzyme-linked immunosorbent assays ............................ 73 
6.12 Intracellular proteins analysis by Western Blotting ......................................... 74 
       6.12.1 Protein extraction ................................................................................... 74 
       6.12.2 Western Blot........................................................................................... 75 
6.13 Sta  ........................................................................................ 75 
Chapter 7  Results ..................................................................................................... 76 
7.1 GHR and CD44 expression on cartilage biopsies and isolated chondrocytes ... 76 
7.2 HYADD®4-G effect on chondrocytes ............................................................... 79 
7.3 Morphology and viability of chondrocytes treated with hGH 
 and HYADD®4-G ............................................................................................ 83 
7.4 Evaluation of chondrocyte metabolic activity ................................................... 87 
7.5 Effect of hGH and HYADD®4-G on GHR and CD44   .................................... 89 
7.6 Effects of hGH and HAD on chondrocyte markers   ......................................... 90 
7.7 Release of IGF-1, FGF-2 and IL6 by treated chondrocytes  .............................. 98 
7.8 Evaluation of SOCS2  ...................................................................................... 101 
Chapter 8  Discussion ............................................................................................. 104 
References  ................................................................................................................ 107 
Acknowledgement .......................................................................................................123 
 
1. Osteoarthritis 
 
1.1 Pathology 
 
Osteoarthritis (OA) is the most common form of arthritis and a major cause of pain and 
disability in older adults (over the age 65) (Blumenkrantz et al., 2004). The prevalence of 
OA in most joints is higher, before 50 years, in men than in women and after this age, 
women are more often affected than men. (Felson et al., 2000) 
  and it is characterized by 
joint pain and limited function of the articulation. This is a misnomer because OA is not 
simply a process of wear and tear but rather abnormal remodelling of joint tissues driven 
by a host of inflammatory mediators within the affected joint. (Loeser et al., 2012).  
Nowadays OA is considered a disease of the whole joint as an organ, the articular cartilage 
is altered to some extent in all affected joints with OA. In addition to the development of 
cartilage changes with aging, cartilage degeneration may occur in response to inappropriate 
mechanical stress and low-grade local systemic inflammation associated with trauma, 
metabolic syndrome, and genetic predisposition, which are major risk factors of OA 
development and progression. However, strong functional interactions among the cartilage, 
synovium, and subchondral bone impact on cartilage function in such a way that it is 
difficult to know where and when pathological changes begin. (Houard et al., 2013) 
Bone, cartilage, synovial fluid, ligaments and also the muscles around the joint are tissues 
that change with OA and affect the function of the joint. (Andriacchi et al., 2009; 
Buckwalter et al., 2004) Several tissues might be a starting point for pathways that lead to 
OA. Cartilage might be the tissue where the pathophysiological process of OA starts, but 
biochemical and imaging studies have shown that synovium and bone could be also good 
starting points. However, it remains unclear which of these three types of tissue, or some 
combination thereof, might serve as the key tissue for OA. (Samuels et al., 2008) 
One of the most affected joints is the knee, in this joint osteoarthritis is a chronic, indolent 
disease that will affect an ever increasing number of patients, especially the elderly and the 
obese. It is characterized by degeneration of the cartilage substance inside the knee which 
leads to pain, stiffness and tenderness. By some estimations in 2030, only in the United 
States, this medical condition will burden 67 million people. (Uth and Trifonov, 2014) 
A diagnosis of OA is mainly based on symptoms. A patient that has reached a certain age 
and has joint pain, limitation of movement, crepitus and, sometimes, effusion in the joint 
might get the diagnosis of OA. Recommendations for the diagnosis of knee OA were 
published in 2010. (Zhang et al., 2010) The treatment of OA is mainly symptom driven 
and based on the use of anti-inflammatory medication in combination with exercise 
treatment and lifestyle changes. However such treatment cannot prevent or cure OA and 
often fails to provide satisfactory pain relief. Joint replacement may be possible in 
developed countries for patients with severe OA and significant disability. Research efforts 
during the past decades have focused on the search for disease-modifying treatments. Most 
of these disease-modifying treatments were directed towards regeneration of the cartilage 
and were tested in patients with evident OA. However, so far, these efforts have not been 
very successful and have not had a significant influence on the symptoms of OA. (Hunter 
2011) 
A more comprehensive definition summarizing the clinical, phatophysiological, 
biochemical and biomechanical changes that occur in OA was summarized in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 1 Features of OA 
Clinical  
 
 
 
 
effects 
Pathological 
increate load 
Sclerosis of subchondral bone 
Subchondral cysts 
Marginal osteophytes 
Increased metaphyseal bood flow 
Variable synovial inflammation 
Histological Fragmentation of cartilage surface 
 
 
on 
vessels 
 
Loss cartilage 
Sclerosis of subchondral bone 
 
Biomechanical 
  
Alteration in tensile, comprensive and shear properties 
Altered cartilage hydraulic permeability 
 
 
Biochemical  
proteogycans 
nd weave 
Increased synthesis and degradation of matrix 
macromolecules 
1.2 Classification 
 
Criteria for classification of symptomatic OA have been developed by a subcommittee of 
the American College of Rheumatology (ACR). The ACR OA criteria were developed to 
standardise the definition of hip, knee and hand OA and are comprised of joint symptoms, 
exclusion of inflammatory conditions and positive radiography.  
The Kellgren-Lawrence (Kellgren and Lawrence, 1957) system for radiographic grading of 
OA has been the standard for several decades and is based upon the presence and severity 
of certain defined radiographic features including osteophytosis, joint space narrowing, 
joint line sclerosis and subchondral cysts. These radiographic features are used to grade the 
severity of OA from 0 (normal joint) to 4 (complete joint space loss). (Shane Anderson and 
Loeser, 2010) 
There are two main types of osteoarthritis, which have differing causes. 
1) Idiopathic osteoarthritis  Idiopathic OA has no identifiable cause. It may be 
localized (confined to one or two joints) or generalized (present in three or more 
joints). 
2) Secondary osteoarthritis  Secondary OA is caused by an underlying condition, 
such as a joint injury, accumulation of calcium inside the joint, other bone and joint 
conditions (e.g. rheumatoid arthritis), or a medical condition, such as diabetes. It 
can be divided into four main categories (Table 2): 
 metabolic disorders such as ochronosis, which lead to joint damage that can be 
indistinguishable from OA; 
 anatomic derangements such as a slipped epiphysis, which can lead to OA of the 
one affected joint only; 
 major trauma or surgery to a joint, such as a meniscectomy; 
 a previous inflammatory arthropathy, such as RA, resulting in a secondary OA 
process in some of the affected joints. 
However, the distinction between primary and secondary OA is not always clear. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Classification of OA 
Classification into primary and secondary forms of OA 
 Primary = idiopathic 
 Secondary indicates that a likely cause can be 
identified 
Causes of secondary OA: 
1. Metabolic: ochronosis, acromegaly, 
hemochromatosis, calcium crystal deposition; 
2. Anatomic: slipped femoral epiphysis, epiphyseal 
-perthes disease, 
congenital dislocation of the hip, leg-lenght 
inequality, hypermobility syndromes; 
3. Traumatic: major joint trauma, fracture through 
a joint or osteonecrosis, joint surgery (e.g. 
meniscectomy), chronic injury; 
4. Inflammatory: any inflammation arthropathy, 
septic arthritis. 
Classification by the presence of specific features 
 Inflammation 
 Erosive OA 
 Artrophic or destructive OA 
 OA with chondrocalcinosis 
 1.3 Epidemiology 
 
OA is the most common rheumatic disease, and it represents 72.6% of rheumatic diseases 
in our country. (De Filippis et al., 2004) In regards to the epidemiology of knee OA is the 
most common joint disorder in the world and one of the most common sources of pain and 
disability. In the elderly studies indicate that knee osteoarthritis in men aged 60 to 64 is 
usually found in the right knee (23%) than in the left knee (16.3%), while distribution 
seems to be more evenly balanced in women of the same age (right knee, 24.2%; left knee, 
24.7%). (Michael et al., 2010) A variety of endogenous (e.g., age, sex) and exogenous 
defined. (Uth and Trifonov, 
2014) 
While there remains considerable heterogeneity in defining OA among epidemiological 
studies, the evidence is conclusive that age remains the greatest risk factor for the 
development of OA in susceptible joints. Radiographic changes, in particular 
osteophytosis, are very common in the aging population and when used alone may provide 
an overestimation of the true prevalence of symptomatic OA. Defining OA solely as joint 
pain occurring in an older adult without evidence for another form of arthritis is also 
inaccurate in fact there are many causes of non articular-pain, such as bursitis, that are 
common in older adults. (Shane Anderson and Loeser, 2010, Li Y et al., 2013) 
The aging however is not the only cause of the disease, but other causes, later discussed, 
also contribute to OA progression. (De Filippis et al., 2004) 
 
 
 
 
 
 
 
 
 
 
 
1.4 Risk Factors 
 
OA is a disease characterized by chronic multifactorial etiology, that includes different 
factors. These factors can increase the risk of developing osteoarthritis; most people with 
OA have one or more of these factors. 
Multiple components of the joint are adversely affected by OA, including the peri-articular 
bone, synovial joint lining, and adjacent supporting connective tissue elements furthermore 
multiple factors, including joint instability and/or malalignment, obesity, increasing age, 
associated intra-articular crystal deposition, muscle weakness and peripheral neuropathy, 
are known to affect the progression of OA. These factors can be segregated into categories 
that include hereditary contributions, mechanical factors, and the effects of aging. 
(Goldring MB and Goldring SR, 2007) 
 
1. Intrinsic factors:  
 Age: Advancing age is one of the strongest risk factors for OA. The condition 
rarely occurs in people younger than age 40, but at least 80% of people over age 55 
have some x-ray evidence of the disorder. However, not all people with arthritis on 
an x-ray have joint pain or other joint problems. The effects of age might by 
mediated through excess joint loading from obesity over time, impaired muscle 
function and neurological responses that otherwise protect the joint (Newman et al., 
2003) and increased joint instability due to ligamentous laxity. Aging may also 
cause a change in the material properties of the tissue involved, in fact aging make 
the cartilage more prone to failure. The repair capacity of the joint is also believed 
to diminish with increasing age. 
 Gender:  For unknown reasons, women are between two and three times more 
likely than men to develop OA. Before age 50, the joint involvement is slightly 
higher in men; while after that age women have a higher incidence, probably due to 
decreased estrogenic activity. 
 Obesity:  People who are obese are at high risk of developing OA. Obesity leads to 
an overload of the joints and to accumulation of cholesterol therefore weight loss 
may reduce this risk. (De Filippis et al., 2004) 
 Ereditariety: some studies have found that OA has an hereditary components, in 
fact some locus have been mapped on different chromosomes. (De Filippis et al., 
2004) 
 Ethnicity: Some data indicate a higher prevalence of OA of the hip in Caucasians 
compared to people of color, while other works indicate a higher prevalence of 
knee OA in a Japanese population compared to a Caucasian. (Nevitt et al., 2002) 
 Genetic factors: Genetics of OA has been the subject of several studies. There is 
now good evidence indicating a genetic contribution to about half the population 
variability in susceptibility to hip and knee OA. A number of susceptibility loci 
have been identified but no single genetic variant has been found that has a strong 
association with OA. (Valdes et al., 2008) 
 Metabolic factors: nutritional factors play a role to increase OA. Low vitamin C 
intake has been associated with accelerated progression of OA, similar data have 
been found with vitamin D. (De Filippis et al., 2004) 
2. Local factors:  
 Occupation: OA of the knee has been linked to certain occupations that require 
frequent squatting and kneeling, including cotton processing, dock work, shipyard 
work, and carpentry. OA of the hip has been linked to farm work, construction 
work, and other activities that require heavy lifting, prolonged standing, or walking 
several miles each day. 
 Sports : The risk of OA is increased in people who participate in some specific 
sports, including wrestling, boxing, pitching in baseball, cycling, parachuting, 
cricket, gymnastics, ballet dancing, soccer, and football; in contrast, running does 
not appear to increase the risk of OA. 
 Alterations joint: produced by diseases of inflammatory nature, post-traumatic 
epiphyseal necrosis, etc. (Litwic et al., 2003) 
 
 
 
 
1.5 Sintomatology 
 
The onset of this disease generally is often gradual and usually affects one or a few joints. 
Pain, functional limitation and morning stiffness are the most clinical characteristic. 
(Chaganti and Lane, 2011) 
Furthermore, as the cartilage substance decreases, the bone surface may also become 
affected. This results in development of osteophytes (bone spurs) and direct bone-bone 
contact. In addition to the stiffness of the joint, the patient tries to avoid pain by 
minimizing joint movement, which leads to muscle atrophy and laxity of the ligaments. 
(Uth and Trifonov, 2014) 
The symptoms of OA usually begin after age 40 and can vary considerably from one 
person to another. 
 Pain  The main symptom of OA is joint pain that is worse with activity and is 
relieved by rest. In severe cases, the pain may also occur at rest or at night. The 
pain usually occurs near the affected joint; however, in some cases, the pain may be 
referred to other areas. For example, the pain of OA of the hip may actually be felt 
in the knee. Joints affected by OA may be tender to the touch. The level of pain is 
typically constant over time. Any sudden increases in the level of pain may indicate 
recent injury or an underlying condition such as gout.  
 Stiffness  Morning stiffness is a common symptom of osteoarthritis. This 
stiffness usually resolves within 30 minutes of rising, but it may recur throughout 
the day during periods of inactivity. Some people note a change in symptoms 
related to the weather. 
 Swelling (effusion)  Osteoarthritis may cause a type of joint swelling called an 
effusion, which results from the accumulation of excess fluid in the joint. 
 Crackling or grating sensation (crepitus)  Movement of a joint affected by 
osteoarthritis may cause a crackling or grating sensation called crepitus. This 
sensation likely occurs because of roughening of the normally smooth surfaces 
inside the joint. 
 Bony outgrowths (osteophytes)  Osteoarthritis often causes outgrowths of bone 
called osteophytes or bone spurs. These bony protuberances can be felt under the 
skin near joints and typically enlarge over time. 
 Symptoms in specific joints  Osteoarthritis does not affect all joints equally. 
The condition most commonly affects the fingers, knees, hips, and spine; it rarely 
affects the elbow, wrist, and ankle. Furthermore, it often affects joints on one side 
of the body differently than on the other side. (Khanna et al., 2012) 
 
1.6 Physiological modification of the OA joints 
 
OA : articular cartilage, 
subchondral bone and synovium. 
 
1.6.1 Articular cartilage 
 
Articular cartilage is avascularized, aneural tissue, and is highly specialized tissue 
constituted by an extensive extracellular matrix (ECM), which is mainly composed of 
water, collagen type 2, collagen type 9, collagen type 11 and proteoglycan (aggrecan). 
(Figure 1) 
The biophysical properties of cartilage derive from this highly organized fibrillar 
framework, that supplies shape, strength, tensile stiffness and compressive resistance to the 
tissue. The synthesis, maintenance and degradation of ECM proteins are coordinated by 
chondrocytes, the only resident cell type in cartilage. (Goldring and Marcu, 2009; Wang et 
al., 2011) 
 
 
 
Figure 1: The extracellular matrix of cartilage is composed of proteoglycans attached to a 
backbone of hyaluronic acid that is intertwined among collagen fibrils. Proteoglycans 
have both chondroitin-sulfate- and keratin-sulfate-rich regions, and link proteins facilitate 
binding of aggrecan to hyaluronic acid. 
 
 
Chondrocytes are the only cells type of the cartilage, encapsulated within a lacuna, which 
hinders their ability to migrate to the site of injury. Chondrocytes do not have the capacity 
for renewal, proliferation, or repair the damage tissue. (Wang et al., 2010) 
 In normal cartilage, there are four zones of chondrocytes: resting cells orientating within 
the collagen fibers in the superficial zone, large and randomly distributed cells in the 
middle zone, columns of chondrocytes in the deep zone, and hypertrophic cells in the 
calcified zone (Figure 2). (Salminen et al.,2002) 
Under normal conditions, articular chondrocytes maintain a dynamic equilibrium between 
synthesis and degradation of ECM components, including collagen type 2 and aggrecan, 
the most abundant proteoglycan in articular cartilage. (Sandell et al., 2001) 
 
 
 
Figure 2: Zonal architecture in normal articular cartilage. 
 
 
 
A series of catabolic and anabolic mediators have been found to play key roles in articular 
cartilage homeostasis. The balance between synthesis and degradation is affected by age 
and is regulated by several factors produced by the synovium and chondrocytes, including 
cytokines, growth factors, aggrecanases, and metalloproteinases (MMPs). 
The pathogenesis of knee OA have been linked to biomechanical and biochemical changes 
in the cartilage of the joint mainly associated to inability to withstand normal mechanical 
stresses, limited supply of nutrients and oxygen, inadequate synthesis of extracellular 
matrix components, increased synthesis of tissue-destructive proteinases (matrix 
metalloproteinases and aggrecanases) and overall apoptosis of chondrocytes (Figure 3). 
(Buja and Krüger, 2014)  
 
 
Figure 3: Main characteristics of normal and OA knee joint 
 
 
Chondrocytes can respond to direct biomechanical perturbation by up-regulating synthetic 
activity or by increasing the production of inflammatory cytokines (e.g. IL- -6, IL-8, 
TNF- , which are also produced by other joint tissues. This process causes depletion of 
proteoglycans and damage to the collagen network and decreases the synthesis of cartilage 
matrix proteins, whereas dynamic compression increases matrix synthetic activity. (Guilak 
et al., 2004) In response to traumatic injury, global gene expression is activated, resulting 
in increased expression of inflammatory mediators, cartilage-degrading proteinases, and 
stress response factors (Figure 4). (Goldring and Otero, 2011) 
 
                 
 
Figure 4:  In osteoarthritis (OA), the balance between cartilage degradation and synthesis 
leans toward degradation. In osteoarthritic state, aberrantly activated chondrocytes 
produce ECM-degrading proteases (MMPs, aggrecanases) and pro-inflammatory 
cytokines (e.g. IL-1). Fragments derived from ECM degradation are also present in the 
synovial fluid as catabolic inducers. In OA, a subpopulation of chondrocytes undergoes 
hypertrophic changes, as manifested by their expression of type X collagen. Chondrocytes 
may also upregulate apoptosis, resulting in diminished local cellularity. In response to 
cartilage loss, pathological remodeling of subchondral bone gives rise to sclerosis and 
osteophyte formation.  
 
 
Chondrocytes have receptors for responding to mechanical stimulation, many of which are 
also receptors for ECM components. (Millward-Sadler and Salter, 2004) The activation of 
these receptors can stimulate the production of matrix-degrading proteinases and 
inflammatory cytokines and chemokines. (Goldring MB and Goldring SR, 2007; Pulai et 
al., 2005) 
The pathological changes of OA in articular cartilage are mainly due to an increase of 
catabolic factors, that cause the loss of ECM and cell apoptosis. Cartilage matrix 
degradation products like collagen type 2, proteoglycans, and fibronectin seem to favour 
cartilage destruction. (Santos et al., 2011) 
A further hallmark of degenerated cartilage is the modification of chondrocyte 
differentiation stage, that switches them toward a hypertrophic phenotype (Goldring and 
Marcu, 2009; Fosang and Beier 2011), thus recapitulating some of the physiological 
differentiation steps occurring in growth plates and endochondral ossification. 
Hypertrophic chondrocytes are characterized by the expression of terminal differentiation 
markers, 
including Runt-related transcription factor 2 (RUNX-2), Collagen 10, MMP-13. (Van der 
Kraan and Van den Berg, 2012) 
In fact, when OA occurs and proceeds, chondrocytes start to express several proteins such 
as biglycan, decorin, perlecan, and collagen type 1 and 10, so forming repaired 
brocartilage. (Moreland, 2003; Lee et al.,2013) 
 
1.6.2 Subchondral bone  
 
Subchondral bone consists of the subchondral bone plate and the underlying trabecular 
bone and bone marrow space. The subchondral bone plate consists of cortical bone and is 
separated from the articular cartilage by the zone of calcified cartilage. 
Subchondral bone properties are modified through the cell mediated process of remodeling 
and modelling. Bone remodeling includes the coupling of mechanisms that reabsorb bone 
and form new bone on a previously reabsorbed surface, whereas bone modeling is a 
mechanism that drives changes in the architecture and volume of bone via direct apposition 
to existing bone surfaces. (Man and Mologhianu, 2014) 
During OA process all of these mechanisms may be altered so resulting in subchondral 
bone structure changes. 
Subchondral sclerosis is commonly considered an indisputable sign of OA. However, some 
studies suggest that different microarchitectural alterations of subchondral bone occur 
during different stages of OA; subchondral sclerosis may be observed only during more 
advanced stages of OA. 
In early stages of OA, elevated bone remodeling and subchondral bone loss was observed, 
and was considered as a determinant of OA progression. (Li et al., 2013) 
An incidence of microdamage (associated with subchondral bone stiffening and cartilage 
degeneration) was also reported in the subchondral bone of patients with early OA. 
Although the underlying mechanism for the increased bone turnover and structural 
deterioration in the early phase of OA is not completely understood, several factors have 
been implicated, including microdamage repair, increased vascularity stimulated by 
angiogenic factors and enhanced bone-cartilage crosstalk via increased subchondral plate 
pores. (Verborgt et al., 2000) 
In the late stage of OA, subchondral bone microarchitectural is characterized by elevated 
apparent density, increased bone volume, thickening of subchondral bone plate, increased 
trabecular thickness, decrease of trabecular separation and bone marrow spacing. (Ding, 
2010) 
The overlying calcified cartilage is also thickened, with advancement and duplication of 
the tidemark, which contributes to articular cartilage thinning and deterioration. Despite 
increased bone volume density in the sclerotic subchondral bone, its mineralization is 
reduced and lower than that in normal or even osteoporotic joints. In OA subchondral 
bone, collagen synthesis is elevated (especially collagen type 1), the deposited collagen is  
abnormal and this leads to abnormal mineralization. (Man and Mologhianu, 2014) 
Moreover, in areas of the joint that not support the weight, usually develop further bone 
and cartilaginous tissue, better known as osteophytes. 
The osteophytes are covered with a layer of hyaline and fibrous cartilage and blends with 
adjacent synovium. 
The shape and position of osteophytes depends on: 
- the instability of the joint; 
- the degree of subluxation. 
However, the presence of osteophytes is not absolute proof of the OA development. 
Summarizing features of OA in the subchondral bone are fibrillation, sclerosis, even 
collapse, together with bone cysts, thickened cortical plate, extensive remodelled 
trabeculae and osteophyte formation surrounding articular margins.  
 
 
1.6.3 Synovial membrane 
 
Clinical evidence shows that OA and synovitis (inflammation of the synovium) are closely 
related. 
Abnormalities of the synovium are detectable in 50% of patients with OA; synovitis is 
detected by some osteoarthritic symptoms that characterize the disease, such as swelling, 
effusion, redness and pain. 
The synovial inflammation is certainly more evident in patients who have pain, and the 
severity of the pain is associated with thickening of the synovial membrane. 
It remains unclear whether the morphological changes that occur in the osteoarthritic 
synovial membrane are primary or whether they are the result of joint inflammation, 
cartilage degradation and lesions of the subchondral bone. (Sutton et al., 2009) 
 Histologically, the synovial membrane of osteoarthritic joints commonly exhibits 
hyperplasia of the lining cell layer occasionally accompanied by focal infiltration of 
lymphocytes and monocytes in sublining layers. (Brandt et al., 2009) 
Synovitis is believed to be induced at first by the cartilage matrix proteolytic degradation 
products that produce wear particles and soluble cartilage-specific neo-antigens, as well as 
other factors including microcrystals and abnormal mechanical stress. These components 
are released into the synovial fluid and are phagocyted by synovial lining macrophages, 
perpetuating the inflammation of the synovial membrane through the synthesis of 
mediators, which in turn diffuse through the synovial fluid into the cartilage, and create a 
vicious circle, with increased cartilage degradation, and subsequently produce more 
inflammation. This also explains the increase in the amount of CD68-positive type A 
synoviocytes (macrophage-like), which have phagocytic capacity, in the synovial lining 
layer. (Martel-Pelletier and Pelletier, 2010)   
The synovium produces some of the chemokines and metalloproteinases that degrade 
cartilage, even though the cartilage itself produces most of these destructive molecules. In 
turn, cartilage breakdown products, resulting from mechanical or enzymatic destruction, 
can induce the release of collagenase and other hydrolytic enzymes from synovial cells and 
lead to vascular hyperplasia in osteoarthritic synovial membranes. (Man and Mologhianu, 
2014) 
Synovial neovascularization may be largely driven by synovitis as inflammatory cells such 
as macrophages that can themselves secrete pro-angiogenic factors. These cells also secrete 
factors that stimulate other cells, such as endothelial cells and fibroblasts, to produce 
vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and 
other factors that further promote angiogenesis. 
Angiogenesis in the synovium is closely associated with chronic synovitis and may occur 
at all stages of osteoarthritis. 
 
 
 
 
 
 
 
 
 
 
1.7 Molecules involved in OA pathophysiology 
 
Numerous mediators contribute to the progression of OA. Inflammatory stimuli initiate a 
cascade of events, including the release of cytokines by chondrocytes, leading to complex 
biochemical and mechanical interplay with other biological mediators to induce OA and 
promote pain. Particular catabolic mediators  include pro-inflammatory members from the 
interleukin family (IL-1, IL-6, and IL-17), tumor necrosis factor-  (TNF- ), and 
prostaglandin E2 (PGE2).  Each of these mediators not only stimulates the production of 
cartilage-degrading proteases to induce ECM degradation, but also contributes to OA-
associated pain pathways. (Bauer et al., 2006) 
On the other hand a number of growth and differentiation factors that regulate cartilage 
development and homeostasis of mature articular cartilage have been identified. The most 
characterized factors which stimulate the anabolic activity in cartilage include transforming 
growth factor (TGF-
(FGF), insulin growth factor 1 (IGF-1). (Vinatier et al., 2009) 
Moreover, since articular cartilage is an avascular tissue and, consequently, chondrocytes 
receive oxygen and nutrients via a passive diffusion from the synovial fluid, and their 
adaptation to low oxygen tension is mediated by transcription factors, such as hypoxia 
inducible factor (HIF). (Schipani et al., 2001) 
 
1.7.1 Interleukin-1 (IL-1) 
 
IL-1 is one of the most well-studied cytokines involved in OA. 
IL-1 demonstrates potent bioactivities in inhibiting ECM synthesis and promoting cartilage 
breakdown, represses the expression of essential ECM components (e.g. aggrecan and 
collagen type  II) in chondrocytes and induces  proteolytic enzymes such as collagenases 
(MMP-1 and MMP-13) and ADAMTS-4, in both chondrocytes and synovial fibroblasts. In 
addition to these direct effects, IL-1  induces a variety of other cytokines, including IL-6, 
IL-8, and leukemia inducing factor (LIF), which interact to induce additive or synergistic 
effects in the catabolic cascade. (Goldring et al., 1988)  
 
 
 
 
1.7.2 Interleukin-6 (IL-6) 
 
IL-6 is a pro-inflammatory cytokine that is involved in cartilage degradation, and it has 
also been associated with hyperalgesia and hypersensitivity in joint tissues. IL-6 plays an 
important role in the pathogenesis of arthritis diseases, and its concentration is elevated in 
the serum and synovial fluid of arthritic patients. (Lee et al., 2013) 
The production of IL-6 in the tissues of the affected joint is usually in response to IL-1  
and TNF  and is mainly implemented by chondrocytes, osteoblasts, fibroblast-like 
synoviocytes, macrophages, and adipocytes. (Wojdasiewicz et al., 2014) 
The effect of IL-6 on joint cartilage is not different from other cytokines and, in synergy 
with them, causes a decrease in the production of type II collagen and increases the 
production of enzymes from the MMPs group. (Porée et al., 2008) 
IL-6 is considered to be the key cytokine, which causes changes in the subchondral bone 
layer. Its effect is largely based on promoting the formation of osteoclasts and thus bone 
resorption while showing synergism with IL-1  and TNF . Osteoblasts stimulated by IL-
1 , TNF , and IL-6 become a source thereof and may also produce MMPs by adversely 
affecting the cartilage located near it. (Wojdasiewicz et al., 2014) 
 
1.7.3 Tumor necrosis factor-  (TNF- ) 
 
TNF- is known for its powerful catabolic effects in the pathophysiology of OA. 
In OA patients, TNF-
subchondral bone and cartilage. TNF- inhibits synthesis of the major extracellular matrix 
(ECM) components: proteoglycans, collagen type II and cartilage link protein. Moreover, 
TNF- up-regulates expression and release of various cartilage-destructive MMPs, like 
MMP-1, MMP-3 and MMP-13. 
It is an extremely potent pro-inflammatory cytokine that interacts with chondrocytes by 
binding to receptors on their surface. (Haseeb and Haqqi, 2013) 
In fact, TNF- has an exacerbating effect on inflammation by inducing production of the 
pro-inflammatory cytokines and chemokines: IL-6, IL-8, IL-1 via the receptors TNFR1 
and TNFR2. (Wojdasiewicz et al., 2014) 
Systemic TNF-
indicating that systemic low-grade inflammation indeed plays a role in OA pathogenesis. 
 
1.7.4 Prostaglandin E2 (PGE2) 
 
During pro-inflammatory states in articular cartilage, numerous enzyme products are 
produced and released, including PGE2, that is considered to be the major contributor to 
inflammatory pain in arthritic conditions. PGE2 exerts its effects via a variety of E 
prostanoid (EP) receptors (EP1, EP2, EP3, EP4), which are present in both peripheral 
sensory neurons and the spinal cord. Activation of these receptors induces a variety of 
effects, ranging from calcium influx to cAMP activation or inhibition 
It has been shown that IL-1  stimulates and produces high levels of PGE2 that may induce 
pain and the degeneration in OA. Further, PGE2, when combined with the catabolic 
cytokine IL-1, synergistically up-regulates IL-6 mRNA levels. (Li et al., 2009)  
 
1.7.5  Fibroblast growth factor (FGF-2) 
 
FGF-2, a potent catabolic and anti-anabolic factor, play an important role in human 
cartilage homeostasis. FGF-2 is released in higher amounts during loading and/or injury of 
the cartilage matrix and activates multiple transduction signal pathways (MAPKs), such as 
ERK, p38, and JNK. These kinases in turn phosphorylate a set of transcription factors to 
regulate gene expression and modify cellular function, resulting in a decrease in 
proteoglycans synthesis and antagonism against anabolic growth factors, such as insulin-
like growth factor 1 (IGF-1) and bone morphogenetic protein (BMP-7) in articular 
cartilage. FGF-2 potently stimulates MMP-13 expression, which is the major type II 
collagen-degrading enzyme. (Im et al., 2008) 
However anabolic activity of FGF-2 in articular cartilage has been reported. (Ellman et al., 
2008) 
In adult cells, the chondrogenic effect of FGF has been confirmed in some studies. In adult 
chondrocytes, it has been shown that FGF2 has various property, in fact it has mainly a 
mitogenic, proliferative and chondrogenic factor. Furthermore, the contradictory results for 
the potential role of various FGFs in chondrogenesis highlight the need for a better 
characterization of the signalling pathways that are activated by FGFs to be able to fully 
understand  how they affect FGF activity. (Vinatier et al., 2009) 
 
 
 
 1.7.6 Insulin-like growth factor (IGF) 
 
The insulin-like growth factor (IGF) family comprises the ligands IGF-1 and IGF-2, the 
receptors IGF1R and IGF2R, at least six different IGF-binding proteins (IGFBPs) and 
multiple IGFBP proteases, which regulate IGF activity. IGF-2 mainly has a role in 
embryonic and foetal development, whereas IGF-1 is more relevant for cartilage repair. 
In adults, IGF-1 and IGF1R are expressed by chondrocytes, osteoblasts and osteoclasts. 
IGF-1 is considered an essential mediator of cartilage homeostasis through its capacity to 
stimulate proteoglycan synthesis and to promote chondrocyte survival and proliferation. 
IGF-1 was also able to induce migration of chondrocytes and, moreover, the combined use 
of chondrocytes and IGF-1 seemed to improve the overall consistency of the repair tissue. 
(Vinatier et al., 2009) 
However, the ability of chondrocytes to respond to IGF-I decreases with age and in OA. 
Evidence suggests an uncoupling of IGF-I responsiveness in OA, indicating that, in OA 
cartilage IGF-I is able to robustly stimulate proteoglycan synthesis, but it is unable to 
modulate proteoglycan catabolism. (Martin et al., 1997) 
 
1.7.7 Hypoxia inducible factor (HIF) 
 
HIF is a heterodimer that consists of the subunit HIF-1  or -2  and the aryl hydrogen 
receptor nuclear translocator (ARNT) subunit, also known as HIF-1 . 
Whereas HIF-1  is stable in normoxic conditions, HIF- 1  and -2  are unstable and are 
rapidly degraded through the ubiquitin proteasome pathway. Under hypoxic conditions, 
HIF-1  and -2  are stabilized and translocate from the cytoplasm to the nucleus, where 
they heterodimerize with ARNT to bind to the hypoxic responsive element (HRE), thereby 
initiating the transcription of hypoxia-specific genes. HIF-1  has been shown to be 
essential for growth arrest and survival of chondrocytes.  
Hypoxia has also been shown to increase the synthesis of ECM proteins in cultured 
chondrocytes in vitro. These data suggest that low oxygen tension is a key regulatory 
factor of proliferation, differentiation and activity of chondrogenic cells. Interestingly, 
hypoxia has also recently been suggested to inhibit the expression of collagen type X, 
which is the major marker of chondrocyte hypertrophy. (Vinatier et al., 2009) 
Furthermore, HIF-1  contributes to the maintenance of ECM homeostasis, inducing the 
gene expression of two main matrix components: collagen II and aggrecan. (Duval et al., 
2009) 
An increasing transcription of HIF-1  in OA cartilage compared to normal samples was 
shown, particularly in the late-stage of the disease. Consistent with this evidence, 
subsequent studies reported a growing number of HIF-1 -positive chondrocytes during OA 
progression and a higher expression of HIF-1  mRNA in degenerated cartilage compared 
to uninjured cartilage. 
In addition to hypoxic conditions, HIF-1  expression can be up-regulated by other factors, 
including inflammatory cytokines (IL-1 and TNF- ), reactive oxygen species and 
mechanical loading, which are all recognized as key players in cartilage damage. (Yudoh 
et al.,2005) 
Since HIF-1  has a pivotal role in supporting chondrocyte survival and cartilage 
homeostasis, these characterize HIF-1  as a key factor for chondrocyte survival promoting 
compensatory mechanisms in response to catabolic modifications of OA cartilage. 
2. Therapeutic treatments for OA 
 
Treatments aim at educating the patient about OA, reducing pain, optimizing and 
maintaining physical function, and preventing or retarding progression of adverse 
structural damage affecting the joint tissues (cartilage, bone, ligament, muscle). Actually 
available treatments include a wide range of non-pharmacologic, pharmacologic and 
surgical modalities. 
The basic premise for the management of patients with symptomatic OA is that it involves 
a combination of both non-pharmacologic and pharmacologic modalities that are 
-
pharmacologic modalities that can be added as necessary for additional symptom control, 
in some cases require the surgery. (Gossec et al., 2007) 
In addition to non-surgical treatments (e.g. physiotherapy, diet rich in vitamin D and 
supportive sport, like swimming), there are several medicinal and homeopathic products on 
the market, which promise pain relief and a decrease in symptoms. However, researchers 
have a keen interest in investigating new treatments to cure OA of the knee. (Uth and 
Trifonov, 2014) 
Currently available pharmacological therapies target palliation of pain and include 
analgesics (e.g., acetaminophen, cyclooxygenase-2-specific inhibitors, non-selective non-
steroidal anti-inflammatory drugs, tramadol, opioids), intra-articular therapies 
(glucocorticoids and/or hyaluronic acid, HA), and topical treatments (i.e. capsaicin, 
methylsalicylate). (Moreland, 2003) 
Treatments are  individual for each patient and they are dependent by severity of pain and 
stiffness of affected joints and by specific response to the treatment. It is important to work 
with a healthcare provider to create an effective and acceptable plan in the long term for 
living with arthritis. 
 
 
 
2.1 Non-pharmacological therapy of osteoarthritis 
Non-pharmacological treatments can substantially improve OA symptoms, and they are 
usually the first treatments recommended.  
They include: 
 Rest: OA symptoms are typically worsened by activity and are improved with rest. 
However, a complete lack of activity can lead to a loss of muscle and joint 
stiffness. If arthritis causes significant pain and inflammation, healthcare provider 
may recommend rest for 12 to 24 hours, followed by a return to usual activities. It 
would seem sensible if something hurts to rest it. This may only be true in acute 
situations and may not hold for chronic conditions.  
Muscle loss is a feature of both rheumatoid arthritis and OA, and so pain is not an 
indicator of musculoskeletal damage. (Hochberg et al., 2012) 
 Weight loss: Obesity is strongly linked to the development of arthritis of the knee. 
Weight loss, even modest weight loss, appears to lower this risk. It is not known if 
weight loss slows the worsening of arthritis in joints that are already affected. 
However, weight loss may reduce joint pain in weight bearing joints, such as the 
hips and knees. (Bliddal et al., 2011) 
Physical therapy and exercise programs: Physical therapy and exercise improve 
flexibility and strengthen the muscles surrounding the joints. People who exercise 
regularly despite their arthritis will typically have less pain and better function than 
those who are inactive. Canes, walkers, electric-powered seat lifts, raised toilet 
seats, and tub and shower bars can reduce the stress on joints and can make it easier 
to perform daily tasks. A physical therapist may suggest these and other assistive 
devices, depending upon the severity and location of arthritis. (Fransen et al., 2001) 
 Vitamins: Studies have linked certain vitamins to joint health, but the role of 
vitamins in arthritis treatment is uncertain. OA is less likely to worsen in people 
who have a high dietary intake of vitamin C (ascorbic acid) and a high dietary 
intake and high blood levels of vitamin D. However, it is unknown if 
supplementation with these vitamins has the same effects or if high dietary intakes 
of vitamins can prevent the onset of OA. 
 Thermoterapy: Thermotherapy has for many years been advocated as a useful 
adjunct to pharmacological therapies. Ice is used for acute injuries and warmth is 
used for sprains and strains. It seems appropriate to use hot and cold packs in 
osteoarthritis knee.  
Applying heat and cold to arthritic joints can help to control arthritis symptoms 
such as pain and stiffness. 
1) Heat therapy: Heat relieves pain and stiffness in arthritic joints. Heat can be applied 
to the joints with hot packs, hot water bottles, heating pads, or electrically heated 
mittens. It is important to avoid burning the skin with heat therapy. To avoid burns, 
hot water bottles should be filled with warm, not boiling, water. Heating pads 
should be set on a timer and used for no more than 20 minutes at a time. The 
heating pad can be reapplied after 20 minutes of no use. 
2) Cold therapy: Cold relieves pain in arthritic joints and reduces muscle spasms. Cold 
can be applied for short periods using ice packs or coolant sprays. People with 
certain medical conditions, such as the Raynaud phenomenon, should not use cold 
therapy. (Brosseau et al., 2003) 
 Transcutaneous electrical nerve stimulation (TENS): A TENS unit delivers a 
mild electrical current to the skin, stimulating nerve fibers in the skin that may 
interfere with the transmission of pain signals from the arthritic joint. The use of 
TENS as an arthritis treatment is controversial. Some studies have found that those 
who use TENS for arthritis of the knee have reduced knee pain, a greater ability to 
bend the knee, and a reduced duration of morning stiffness. However, another study 
found that TENS was no more effective for relieving pain than the drug naproxen 
(Aleve, Anaprox) or a placebo. (Hochberg et al., 2012) 
 Dietary supplements  Glucosamine and chondroitin are dietary supplements that 
have received a lot of attention for their potential benefit in reducing pain and in 
slowing the progression of arthritis. 
1) Glucosamine: Glucosamine was no more effective in relieving arthritis pain or 
in improving function than placebo in a well-designed, controlled trial; it is 
possible that other formulations may be effective. Glucosamine does not appear 
to slow the worsening of arthritis over the long term. There are few side effects 
of glucosamine; it should not be used by patients who are allergic to shellfish. 
2) Chondroitin: Chondroitin used alone appears to provide little benefit for people 
with OA. There are no significant side effects of chondroitin. 
The combination of glucosamine and chondroitin sulfate has not proven to be better than 
placebo for pain relief or for functional improvement in patients with OA of the knee. 
(Clegg et al., 2006) 
 
 Traditional Chinese medicine: Several components of traditional Chinese 
medicine, including herbs and acupuncture, may help control the arthritis 
symptoms in some people, although the benefits of these therapies have not been 
confirmed in large, well-designed clinical studies. Reumalex, willow bark, stinging 
nettle, Articulin-F, d
(ASU), and Phytodolor may improve arthritis pain, while other herbs and 
combinations such as Eazmov, Gitadyl, or ginger extract are probably ineffective. 
(Vickers et al., 2012) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 Pharmachological treatments of osteoarthritis  
 
An appropriate pharmacological treatment forms is the main key for treating osteoarthritis 
when non-pharmacological therapy on its own is insufficient. The use of such analgesia 
may be use to cure different kind of pain, including night pain or exercise-associated pain. 
Oral analgesics, especially paracetamol, have been used for many years, with increasing 
use of opioid analgesics in recent years, partly fuelled by fears over the safety of NSAIDs. 
(NICE, 2014) 
Pharmacologic modalities could potentially be divided into topical, intra-articular and oral 
(systemic) agents. Furthermore, those that relieve symptoms may have a rapid or slow 
onset of effect. 
 
 Topical agents: Some people experience relief of arthritis pain when they apply 
creams containing capsaicin, the active substance in hot chili peppers. Capsaicin 
depletes a pain-causing substance in nerve endings and lessens the arthritis pain by 
about 30 percent in some people. Forty percent of people experience side effects 
when using capsaicin cream, including burning, stinging, and redness of the skin 
and especially the eye. (Vaile and Davis, 1998) There are a variety of non-steroidal 
anti-inflammatory drug (NSAID) preparation that are available for topical 
application. Analgesics relieve pain but do not have any effect on inflammation. 
These drugs are often recommended when arthritis pain does not respond to non-
pharmacologic measures. Drugs in this class include acetaminophen and opioid 
(narcotic) analgesics. Acetaminophen (Tylenol and others) can relieve mild to 
moderate arthritis pain. To avoid the serious but rare side effects of kidney and/or 
liver damage due to acetaminophen, it is important to follow dosing instructions 
and to avoid drinking excessive amounts of alcohol. The sudden pain, severe 
arthritis exacerbations may require treatment with narcotic analgesics such as 
codeine. Narcotics should be taken for only short periods of time because they can 
be addictive.  
 
 
 
 
 
  Intra-articular therapy: Two types of injections are used for people with arthritis 
pain: corticosteroid injections or hyaluronic acid injections. 
 
1. Corticosteroid injections: Corticosteroid can suppress inflammation and can relieve 
arthritis symptoms when injected into arthritic joints. corticosteroid injections may 
be recommended for people who have OA confined to a few joints and who still 
have pain despite the use of NSAIDs. Corticosteroid injections may also be 
recommended for people with OA who cannot take NSAIDs. Joint injections have 
few side effects, but some people experience a brief flare of arthritis symptoms 
after an injection. There is also a small risk of joint infection. Glucocorticoids may 
damage certain joints when injected frequently. Therefore, clinicians recommend 
no more than three to four injections per year for each particular weight bearing 
joint such as a knee. Corticosteroids have not only anti-inflammatory effects but 
also immunosuppressive effect. The presence of an effusion is not in itself an 
indication for corticosteroid injection, unless there is significant restriction of 
function associated with the swelling. Rather, the indication should be based on 
severity of pain and disability. (Jevsevar, 2013) 
 
2. Hyaluronic acid (HA) injections  Normal joint fluid contains a large amount of 
hyaluronic acid, which allows the joint fluid to be slippery. Synthetic HA may be 
injected into the knee to treat arthritis. After the injection, pain relief may last for 
several months. HA is generally injected in the knee, but their use in other joints is 
being studied. Joint inflammation can occasionally occur after this type of injection 
and as with steroids, it is possible a small risk of infection. HA injections are 
generally reserved for people with OA who cannot take NSAIDs or who do not 
achieve adequate pain relief with them. People awaiting joint surgery may benefit 
from these injections. HA is administered as 3-5 intra-articular weekly injections 
and is generally well tolerated, with a low incidence of local adverse events (from 
0% to 13% of patients) that was similar to that found with placebo.  
Because the residence time of exogenously administered HA in the joint is 
relatively short (approximately less than 26 hours), a variety of chemical 
modifications of the molecule, such as coupling or cross-linking, have been tested 
as a means of increasing both residence time and viscoelastic properties. 
(Borzacchiello et al., 2010; Larsen et al., 2008) 
HA is a large, linear glycosaminoglycan and is a major non-structural component 
of both the synovial and cartilage extracellular matrix. It is also found in synovial 
fluid and is produced by the lining layer cells of the joint. HA is removed from the 
joint via the lymphatic circulation and degraded by hepatic endothelial cells. Its key 
functions in the joint are to confer viscoelasticity, lubrication and help maintain 
tissue hydration and protein homeostasis by preventing large fluid movements and 
umbilical cord tissue and developed for clinical use in ophthalmic surgery and 
arthritis in the 1960s. The beneficial effects in ophthalmic surgery were followed 
by the use of HA in osteoarthritis: the rationale was to replace the properties lost by 
reduced HA production and quality as occurs in osteoarthritis joints, a concept 
known as viscosupplementation. Commercial preparations of HA have the same 
structure as endogenous HA although cross-linked HA molecules (known as 
hylans) were later engineered by linking HA molecules in order to obtain greater 
elastoviscosity and intra-articular dwell-time. However, the mechanism by which 
HA exerts its therapeutic effect, if any, is currently unknown, and evidence for 
restoration of rheological properties is lacking. It has been suggested that two 
stages might be involved; an initial biomechanical stage followed by a 
physiological stage. It is suggested that biomechanical mechanisms initially come 
into effect when the synovial fluid in the osteoarthritic joint is replaced by the 
higher molecular weight exogenous HA. Clinical studies report that exogenous HA 
contribute in restoring the elastoviscosity, and the lubricating and shock absorbing 
abilities, of synovial fluid. It is noted that physiological mechanisms may account 
for the clinical benefits of intra-articular administration of HA that persist beyond 
the residence time of HA, although evidence has largely been obtained from 
preclinical studies. Given the relatively short intra-articular residency (hours to 
days), any hypothesis for its mechanism of action must account for the sometime 
reported long-duration of clinical efficacy (months). (Lohmander et al., 1996; 
Altman and Moskowitz, 1998) 
Nowadays the development of pharmacological treatments with the potential for 
structure-modifying activity in OA joint treatment has become a major focus in the 
field of OA research. Such compounds retard or stabilize the progression of 
established OA by altering the underlying pathological processes. There is a 
growing body of preclinical and clinical data, which suggests that intra-articular 
injection of hyaluronan (HA) has a disease-modifying effect, in addition to its 
proven efficacy and safety in treating the OA patients, aimed at relieving pain and 
regaining function. (Grishko et al., 2009; Elron-Gross et al., 2008) 
 
 Oral pharmacological agents: This group of agents includes analgesics such as 
non-opioid analgesics (e.g. paracetamol) and opioid analgesics, or anti-
inflammatory agents such as NSAIDs. 
 
1. Non-opioid analgesics: for many patients with OA, relief of mild to moderate 
joint pain can be achieved with paracetamol. However, in several trials, 
NSAIDs have been more efficacious, particularly in those with moderate to 
severe symptoms from their OA. (Altman and Moskowitz 1998) 
2. Opioid analgesics: there is limited published clinical research, weak opioid 
analgesics have been commonly administered for OA. Stronger narcotics or 
narcotic derivatives are useful in selected patients with OA. Narcotics are used 
most often as rescue medications for severe pain 
3. Non- steroidal anti-inflammatory drugs: NSAIDs relieve pain and reduce 
inflammation. Many of the nonprescription products that are available for 
treating arthritis pain are NSAIDs. These drugs are often recommended before 
analgesics for people who have osteoarthritis and evidence of inflammation. 
They are also recommended for some people with non-inflammatory OA who 
do not get adequate pain relief with simple analgesics. Non-steroidal anti-
inflammatory drugs (NSAIDs) have been available for many years and are 
thought to work by reducing the production of pro-inflammatory and pain-
related prostaglandins. The discovery of different cyclooxygenase (COX) 
enzymes with different physiological actions brought with it the concept that 
differential blockade of COX-1 (important in normal regulation of the gastro-
intestinal (GI) mucosa) and COX-2 (up-regulated at sites of inflammation 
amongst other functions and thought responsible for pro-inflammatory mediator 
production) may provide effective analgesic/anti-inflammatory actions without 
the common GI complications of traditional NSAIDs. These GI complications 
are well known to clinicians and include a spectrum of problems from 
dyspepsia and ulcers to life-threatening ulcer perforations and bleeds. However 
the blocking of COX-2 always carried the potential for a pro-thrombotic effect, 
by changing the balance of pro- and anti-thrombotic mediators. (NICE, 2014; 
Camu et al., 2002) 
 
2.3 Differents agents 
Although research continues into symptom-modifying medications for OA, there is a new 
emphasis on the development of structure modifying agents. Structure modifying 
medications are intended to retard, prevent or reverse the progression of OA. 
Several groups of agents are under investigation, mostly directed at cartilage repair: 
- Growth factors and cytokine 
- Sulphated and non-sulfated sugars 
- Hormones and other steroids 
- Enzyme inhibitors 
- Chondrocytes/stem cell transplantation 
- Hyaluronan with structure-modifying 
 
2.4 Surgery 
Surgery is usually reserved for severe arthritis that significantly limits your activities and 
that does not respond to other arthritis treatments.  
Furthermore, those who undergo surgery should be in the best possible physical condition 
and should be prepared for rehabilitation after surgery. 
Only 5% of OA patients need surgical treatment when conservative treatment displays no 
satisfactory effect. There are four categories of surgical procedures: osteotomy, 
arthroscopy, arthrodesis, and arthroplasty.  
The purpose of the osteotomy is to transfer the load bearing from the pathologic to the 
normal compartments of the knee. Thirteen studies involving over 693 people indicated 
that valgus high tibial osteotomy is effective in improving knee function and relief of pain. 
However, it is uncertain which treatment, osteotomies or conservative treatment is more 
effective. Furthermore, a successful result of the osteotomy (about 60.3%) depends on 
proper patient selection, stage of osteoarthritis, and achievement and maintenance of 
adequate operative correction.  
Arthroscopy is an alternative procedure to osteotomy. It is not only useful for the treatment 
of the same symptoms, but also for diagnosis of the disease. Although arthroscopic 
methods are widely used, they are not suitable for patients who have displayed OA 
symptoms for more than 2 years, or who display tibial osteophytes and joint space 
narrowing of less than 5 mm. Arthroscopy is effective only temporarily in reducing the 
pain of mild to moderate hip OA.  
Arthrodesis is an efficient procedure for OA of the hands, feet, ankles, and spine, but 
usually not for the hip and knees. 
Arthroplasty refers to the insertion of an artificial joint in order to restore the integrity and 
the function of the joint withered by OA. Joints commonly deteriorate after more than ten 
years, depending on the composition. The perioperative morbidity of unicompartmental 
knee arthroplasty would be less than total knee arthroplasty; furthermore, this arthroplasty 
has been reported to be used in very elderly patients (79-94 years) with tricompartment 
OA. Therefore, age is not a limiting factor for this surgical treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Hyaluronic acid (hyaluronan) 
 
Hyaluronic acid, also called hyaluronan (HA) is a carbohydrate, more specifically a 
mucopolysaccharide, occurring naturally in all living organisms. It can be several 
thousands of sugars (carbohydrates) long. When not bound to other molecules, it binds to 
extracellular matrix and pericellular matrix, but has also been shown to occur 
intracellularly. The biological functions of HA include maintenance of the elastoviscosity 
of liquid connective tissues such as joint synovial and eye vitreous fluid, control of tissue 
hydration and water transport, supramolecular assembly of proteoglycans in the 
extracellular matrix, and numerous receptor-mediated roles in cell detachment, mitosis, 
migration, tumor development and metastasis, and inflammation. (Toole and Hascall 2002; 
Turley et al., 2002) 
The unique viscoelastic nature of HA along with its biocompatibility and non-
immunogenicity has led to its use in a number of clinical applications, including the 
supplementation of joint fluid in arthritis (Medina et al., 2006), as a surgical aid in eye 
surgery, and to facilitate the healing and regeneration of surgical wounds. (Necas et al., 
2008) 
In addition the high exclusion properties of HA molecules restrict the entry of plasma 
proteins into the aqueous phase of synovial fluid. This exclusion effect is dependent  on the 
molecular weight (MW) of the proteins. 
By contrast HA facilitates the transport of water and smalls solutes through synovial fluid 
to articurlar cartilage from capillaries in the synovium and reduces fluid loss as intra-
articular (IA) pressure is raised during joint flexion. These properties of HA are important 
for the nutrition of articular cartilage as well as for the elimination of metabolites and 
noxious substance from the joint cavity. (Gosh and Guidolin, 2002) 
 
 
 
 
 
 
 
3.1 Biochemistry of hyaluronan 
 
HA is a linear polysaccharide composed of repeating disaccharide units, 1,4-glucuronic 
acid (GlcUA) and 1,3-N-acetylglucosamine (GlcNAC). HA belongs to the group of 
glycosaminoglycans, but unlike chondroitin sulfate or keratan sulfate, HA is not sulfated. 
HA is synthesized by bioactivity of hyaluronan synthase (HAS), which has been reported 
to have three isoforms (HAS1, HAS2, and HAS3) in humans. (Masuko et al., 2009) 
HA is characterizes by an high molecular weight (Figure 5) and its relatively simple 
structure is conserved throughout all mammals, suggesting that HA is a biomolecule of 
considerable importance. (Necas et al., 2008) 
 
 
Figure 5: Chemical structure of HA 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 HA receptors 
 
HA plays several important organizational roles in the extracellular matrix (ECM) by 
binding with cells and other components through specific and nonspecific interactions. 
Receptors are constituents of the extracellular matrix, and stabilize its integrity. 
Hyaluronan receptors are involved in cellular signal transduction. It is now widely 
accepted that HA binds to specific receptors, CD44, ICAM-1, LYVE-1 and RHAMM, that 
are expressed by a wide range of cells, including those implicated in the pathology of OA 
(e.g. inflammatory cells, synoviocytes and chondrocytes). (Banerji et al., 1999) The 
finding of specific cell receptors for HA, notably CD44, support a pharmacological 
mechanism of action for this GAG in OA, and because these receptors are widely 
distributed on the surfaces of many types of cells, it also accounts for the diversity of its 
effects. 
CD44 is a structurally variable and multifunctional cell surface glycoprotein expressed on 
most cell types, including macrophages and hepatocytes, and has been implicated in many 
biological process. (Kang et al., 2013) CD44 has been reported to regulate a variety of 
inflammatory responses, including the induction of pro-inflammatory cytokines and the 
migration of macrophages and neutrophils. (Hollingsworth et al., 2007) 
ICAM: also known as CD54 (Cluster of Differentiation 54) is a protein that in humans is 
encoded by the ICAM1 gene. This gene encodes a cell surface glycoprotein which is 
typically expressed on endothelial cells and cells of the immune system. 
LYVE-1: the first identification of an HA receptor that is almost exclusively expressed on 
lymph vessels and is absent from blood vessels. (Banerji et al., 1999) 
RHAMM (Receptor for HA-Mediated Mobility), has been found on cell surfaces, as well as 
in the cytosol and nucleus. (Leach et al., 2004) It has been implicated in regulating cellular 
responses to growth factors and plays a role in cell migration, particularly for fibroblasts 
and smooth cells. (Necas et al., 2008) 
The binding of HA to CD44 and RHAMM and their various isoforms has been reported to 
trigger a variety of intracellular signal events, such as the protein phosphorylation 
cascades, cytokine release and stimulation of cell cycle proteins. (Gosh and Guidolin, 
2002) 
3.3 Mechanism of action 
 
HA is highly hygroscopic and this property is believed to be important for modulating 
tissue hydration and osmotic balance. (Dechert et al., 2006) In addition to its function as a 
passive structural molecule, HA also acts as a signalling molecule by interacting with cell 
surface receptors and regulating cell proliferation, migration, and differentiation. (Necas et 
al., 2008) 
Synovial cells, fibroblasts and chondrocytes synthesize and secrete HA into the joint, 
contributing to enhance viscosity and elastic nature of synovial fluid. In the osteoarthritic 
joint, synovial inflammation leads to increased permeability of the synovial membrane for 
HA. Also, the elevated synovial fluid levels of free radicals, inflammatory cytokines, and 
proteolytic enzymes in osteoarthritic knees impair HA function and contribute to the 
progression of OA. Therefore in OA, both the molecular weight and the concentration of 
HA are decreased. (Moreland, 2003) 
The intra articular injection of HA is thought to restore normal viscoelastic properties of 
the pathologically altered synovial fluid, which explains why it was defined the term of the 
. (Balazs and Denlinger, 1993) 
Moreover, several studies suggest that viscosupplements also have disease modifying 
effects, such as reduction of synovial inflammation, protection against cartilage erosion 
(Amiel et al., 2003), and promotion of intra-articular HA production.  (Ayhan et al., 2014) 
HA possesses a number of functions that may provide some additional chondroprotective 
effects and may explain its longer term effects on articular cartilage.  
3.3.1 Condroprotective effects 
 
The physical properties of HA are important but there is evidence to suggest that HA may 
provide both physiochemical and pharmacological advantages. Chondrocytes express the 
glycoprotein CD44 on their cell surface. This has the capacity to function as a HA receptor 
and so may be involved in biochemical interactions with chondrocytes. The effect of a HA 
injection may be mediated via CD44 interactions. (Necas et al., 2008) 
Therefore, HA has important chondroprotective effects, indeed covers the articular surface 
and exerts mechanical protection on synoviocytes of the articular cartilage, preventing cell 
damage by mechanical stress. In articular cartilage HA allows the organization of 
proteoglycans in huge aggregates and act as a filter against the free diffusion of molecules 
through the synovial membrane. Maintenance of normal structure of HA is essential for the 
homeostasis of the environment and any event that could change the physiological 
characteristics of this polysaccharide can cause serious repercussions.  
 
3.3.2 Effects of hyaluronan on the extracellular matrix 
 
Beneficial effects on proteoglycans synthesis have also been demonstrated in vitro with 
HA. This glycosaminoglycan has been shown to increase proteoglycans synthesis in equine 
articular cartilage, rabbit chondrocytes, and bovine articular cartilage treated with IL-1, 
which has been shown to reduce proteoglycans synthesis in vitro. An increase in high-MW 
proteoglycans production was also demonstrated with HA in cells of rabbit ligament. 
(Ghosh et al., 1995)  
HA also reduced the expression of IL-1  and stromelysin (MMP-3), two mediators known 
to play a role in cartilage degradation. (Takahashi et al., 1999)  
A reduction in collagen gene expression induced by IL-1  in rabbit articular chondrocytes 
has also been suppressed by HA. In an in vivo model of canine OA, a reduced amount of 
glycosaminoglycan release was found in HA-treated joints compared with an increased 
release in untreated joints. 
HA has also been shown to suppress cartilage damage by fibronectin fragments in vitro 
and in vivo. This protective effect was associated with its coating of the articular surface, 
suppression of fibronectin-fragment-enhanced stromelysin-1 release, increased 
proteoglycan synthesis, and restoration of proteoglycans in damaged cartilage. (Moreland, 
2003) 
 
3.4 Viscosupplementation 
 
HA plays a vital role in the development of cartilage, the maintenance of the sinovial fluid 
and the regeneration of tendons. High concentrations of HA have been found in the ECM 
of all adult joint tissues, including the sinovial fluid and the outer layer cartilage. (Leach et 
al., 2004) 
HA has viscoelastic nature and ability to form highly hydrated matrices, and acts in the 
joint as a lubricant and shock absorber. The pathologic changes of synovial fluid 
hyaluronic acid, with its decreased molecular weight and concentration, led to the concept 
of viscosupplementation. 
The concept of viscosupplementation with hyaluronic acid, namely the intra-articular 
injection of the same for the treatment of osteoarthritis, was introduced for the first time by 
Balazs and Denlinger 70s (Balazs and Denlinger, 1993) and in 1997 that practice has been 
approved by the Food and Drug Administration (FDA). 
It is a novel, safe, and possibly effective form of local treatment for osteoarthritis. (Uthman 
et al., 2003) Viscosupplementation with HA products helps to improve the physiological 
environment in an osteoarthritic joint by supplementing the shock absorption and 
lubrication properties of osteoarthritic synovial fluid. The rationale for using 
viscosupplementation is to restore the protective viscoelasticity of synovial HA, decrease 
pain, and improve mobility. The immediate benefits of viscosupplementation are the relief 
of pain. Longer-term benefits are believed to include the return of joint mobility by the 
restoration of trans-synovial flow and, ultimately, the metabolic and rheologic homeostasis 
of the joint. (Wang et al., 2004) 
Viscosupplementation came into clinical use in Japan and Italy in 1987, in Canada in 1992, 
in Europe in 1995, and in the United States in 1997. (Necas et al., 2008) 
The mechanism of action of intra-articular injection of hyaluronic acid is greatly 
influenced by the molecular weight, in fact low molecular weight HA prevails the 
biological activity, while high molecular weight HA is better in performing rheological and 
analgesic activities. (Maneiro et al., 2004) 
Currently in the market there are several formulations of hyaluronic acid injectable 
approved for the treatment of osteoarthritis in the knee, These preparations are different in 
origin, production methods, molecular weight, half-life in the synovial fluid, rheological 
properties, pharmacodynamics and costs. 
 
3.5 HYADD®4-G 
 
Intra-articular (IA) sodium hyaluronate has proven efficacious and well tolerated for the 
treatment of pain associated with knee OA, but optimal molecular weight of HA and 
dosing regimen is still not known. Hyaluronic Acid alone is not suitable for a prolonged 
release of a drug or a protein in the joint, due to its biodegradability and to the immediate 
dilution effect with synovial fluid. 
It has been synthesized a new product: a hyaluronan amide derivative of 500 730 kDa 
(HYADD®4-G), that it has been produced via amidation of the polymer carboxyl groups 
by long chain alkyl amine to enhance the rheological properties and longer residence time 
in the joint cavity compared with native HA. (Finelli et al., 2009) 
HYADD®4-G is a physical hydrogels based on HA modification, of interest to the 
biomedical industry.  
The high molecular weight of HA together with its high degree of hydration allows 
multiple chains to organize themselves to form a dynamic structure of reticular type 
(Figure 6) with two main functions in the physiological concentration (3 mg / ml): 
1) Create molecular scaffold with internal architecture to maintain the shape and tone 
of the tissue, 
2) Function as a filter against the free diffusion in the tissue of particular substances, 
bacteria, infectious agents. 
 
Figure 6: Biochemical structure of HYADD®4-G 
 
The chemical modification of HA has been used in medicine as a main component of 
polymer scaffolds for tissue engineering and as a material used for drug delivery. 
As shown in Figure 7, the hydrogel HYADD®4-G is a physical hydrogel clear and 
transparent, free of macroscopic in homogeneity. 
 
 
Figure 7: Syringe of HYADD®4-G 
 
 
In this hydrogel modification consists in the introduction of hydrophobic aliphatic chains 
C16 glucuronica unit of the polysaccharide with a low degree of substitution (~ 2 mol% 
replacement / mol of repeating unit), produced on an experimental basis by the Fidia 
Farmaceutici S.p.A.  
The result of this substitution is a physical hydrogel injection stable even at very low 
polymer concentrations (0.3-0.8% w / w). In these systems the amount of saline solution is 
99.2-99.7% of the total mass. The structural and dynamic characterization of this system 
showed that the formation of the gel is due to hydrophobic interactions between the side 
chains on the main polymer chain aliphatic introduced, despite the low degree of 
substitution. (Finelli et al., 2009) 
Hydrogels are a class of compounds that are used in more applications in the food industry 
or in the pharmaceutical and biomedical field. Physical gels of polysaccharides are used in 
large scale as food additives or as thickeners. Also the chemical gels have many 
applications, particularly in the biomedical and pharmaceutical fields, with the synthesis of 
biocompatible materials and can respond selectively and reversibly to external stimuli 
(such as changes in pH, temperature, ionic strength) by varying their properties. 
This HYADD®4-G biopolymer has been shown to exhibit on OA chondrocytes and 
synoviocytes a reduction in inflammatory and matrix degradative factors. (Brun et al., 
2012; Smith et al., 2013) 
Moreover, another study performed in an ovine model of OA showed that HA treatment 
decreased synovial vascularity and fibrosis as this HYADD®4-G biopolymer, which also 
significantly increased synthesis of high MW HA by synovial fibroblasts. (Smith et al., 
2008) 
 
4. Growth hormone 
 
Growth hormone (GH), commonly known as somatotropin, is the major growth 
stimulating hormone of the body. It is a single-chain polypeptide and produced  in pulsatile 
manner by the anterior lobe of the pituitary gland as a 22 kDa molecule. It is a polypeptide 
chain containing about 191 amino acid residues, and is responsible for a number of 
anabolic processes (Figure 8). (Denko and Malemud 2005) 
In children as well as adults, GH is secreted in short-term episodic and pulsatile patterns, 
suggesting that the physiological effects of GH are tightly regulated by its release from the 
pituitary gland. Moreover, episodic GH release is affected by gender, age and sleep. 
(Cornford et al., 2012) 
 
 
Figure 8: GH amino acid sequence with disulfide bridge. 
 
It is found that human growth hormone (hGH) has a three-dimensional structure containing 
a four-helical bundle with unusual linkage (Figure 9); the helices run up-up-down-down 
instead of the more common up-down-up-down topology. -Helix 1 and 4 (the NH2- and 
COOH-terminal helices) are also longer than the other two helices. Helices 1-2 and 3-4 are 
connected by a long crossover connection whilst helices 2 and 3 are connected by a much 
shorter segment. At the NH2-terminus, eight amino acid residues extend away from the 
molecule whereas the COOH-terminus is linked to helix 4 by a disulfide bond. A second 
disulfide bond can be found between the first crossover connection and helix 4. Like most 
other peptides, the core of the 4-helical bundle consists of more hydrophobic residues. 
(Cunningham and Wells, 1991) 
 
Figure 9: Three-Dimensional structure of human Growth Hormone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1 Physiologic Effects of Growth Hormone 
Growth hormone is a major participant in control of several complex physiologic 
processes, including growth and metabolism. Growth hormone is also of considerable 
interest as a drug used in both humans and animals. 
A critical concept in understanding growth hormone activity is that it has two distinct types 
of effects (Figure 10): 
 Direct effects are the result of growth hormone binding its receptor on target cells.  
 Indirect effects are mediated primarily by an insulin-like growth factor 1 (IGF-1), 
a factor that is secreted from the liver and other tissues in response to growth 
hormone. A majority of the growth promoting effects of growth hormone is 
actually due to IGF-1 acting on its target cells. 
 
 
Figure 10: Schematic effects of growth hormone 
Keeping this distinction in mind, we can discuss two major roles of growth hormone and of 
IGF-1 in physiology. 
 
 
 
 
 
Effects on Growth  
 
Growth is a very complex process, and requires the coordinated action of different 
hormones. The major role of growth hormone in stimulating body growth is to stimulate 
the liver and other tissues to secrete IGF-1. 
IGF-1 enhances cell proliferation, maturation and differentiation of many tissues including 
bone and skeletal muscle, for example, IGF-I stimulates proliferation of chondrocytes 
(cartilage cells), resulting in bone growth. Growth hormone does seem to have a direct 
effect on bone growth in stimulating differentiation of chondrocytes.  
IGF-I also appears to be the key player in muscle growth. It stimulates both the 
differentiation and proliferation of myoblasts. It also stimulates amino acid uptake and 
protein synthesis in muscle and other tissues. (Alvarez-Garcia et al., 2012) 
 
Metabolic Effects  
 
Growth hormone has important effects on protein, lipid and carbohydrate metabolism. 
These effects can be directly mediated by growth hormone or it can exert indirect effect 
through the critical mediator IGF-1. 
- Protein metabolism: In general, growth hormone stimulates protein anabolism in 
many tissues. This effect reflects increased amino acid uptake, increased protein 
synthesis and decreased oxidation of proteins. (Chikani and Ho 2013) 
- Fat metabolism: Growth hormone enhances the utilization of fat by stimulating 
triglyceride breakdown and oxidation in adipocytes. 
- Carbohydrate metabolism: Growth hormone is one of a battery of hormones that 
serves to maintain blood glucose within a normal range. Growth hormone is often 
said to have anti-insulin activity, because it supresses the abilities of insulin to 
stimulate uptake of glucose in peripheral tissues and enhance glucose synthesis in 
the liver. Somewhat paradoxically, administration of growth hormone stimulates 
insulin secretion, leading to hyperinsulinemia. (Vijayakumar, et al., 2011) 
 
 
 
 
4.2 Secretion and regulation of Growth Hormone 
 
Production of growth hormone is modulated by many factors, including stress, exercise, 
nutrition, sleep and growth hormone itself. However, its primary controllers are two 
hypothalamic hormones and one hormone from the stomach:  
 Growth hormone-releasing hormone (GHRH) is a hypothalamic peptide that 
stimulates both the synthesis and secretion of growth hormone. 
 Somatostatin (SS) is a peptide produced by several tissues in the body, including 
the hypothalamus. Somatostatin inhibits growth hormone release in response to 
GHRH and to other stimulatory factors such as low blood glucose concentration. 
 Ghrelin is a peptide hormone secreted from the stomach. Ghrelin binds to 
receptors on somatotrophs and potently stimulates secretion of growth hormone. 
Secretion occurs in a pulsatile manner under both positive and negative control of the 
hypothalamus and under the influence of these important hypothalamic hormones together 
with peptides such as ghrelin through positive and negative feedback mechanisms, it is also 
an age-dependent secretion, in fact decrease with age. (Denko and Malemud, 2005) 
Secretion of hGH is highest within one hour after the onset of sleep. Other conditions 
during which hGH release is amplified are physical stress, exercise and fasting, while an 
excess of glucose and lipids inhibits hGH release in a healthy individual. (Ritsche et al., 
2014) 
Basal GH levels are low, usually less than 5 ng/mL for most of the day and night In 
children and young adults, the most intense period of growth hormone release is shortly 
after the onset of deep sleep (Figure 11). (Takahashi et al., 1968) 
  
Figure 11:Schematic presentation of growth hormone regulation 
 
 
4.3 The growth hormone receptor and signal transduction 
 
GH exerts its actions on tissues through the GH receptor (GHR). GHR is a key regulator of 
postnatal growth and has important actions on metabolism, reproductive, gastrointestinal, 
cardiovascular, hepatobiliary, and renal systems, so it is required for normal human growth 
and development. (Tsukazaki et al., 1994) 
The receptor is a member of the cytokine receptor superfamily that are found on various 
cell types generally involved with cell growth, proliferation, apoptosis and differentiation. 
(Rico-Bautista et al., 2005)  
The GH receptor is a 620 amino-acid, single chain glycoprotein with a single 
transmembrane domain and an extracellular domain involved in GH signaling. This 
extracellular part, known as the human growth hormone binding protein (GHBP) of which 
there are two classes, also occurs separately in the blood circulation in nanomolar 
concentrations, where they will bind with a substantial part of plasma hGH. (Kato et al., 
2002) 
GHR has a half-life of around 1 hour and is continuously degraded even the absence of 
GH. 
The majority of GHR resided in the endoplasmatic reticulum and cell surface, however 
there was pronounced nuclear localization in many cells, and was demonstrated that 
nuclear GHR is a common feature of tissue and in cells high proliferative status. (Conway-
Campbell et al., 2008) 
Upon binding its receptor, GH can activate several different signaling pathways including: 
mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK); 
Insulin receptor substrate 1 (IRS-1)/phosphatidylinositol 3-kinase (PI3K); phospholipase 
C/protein kinase C/Ca2+. However, the majority of signaling occurs through the best 
characterized pathway Janus kinase (JAK)/signal transducer and activator of transcription 
(STAT) signaling. (Frank, 2008; Gevers et al., 2009) 
The best characterized is the JAK-STAT5b pathway, in which GH-induced JAK2 
activation phosphorilates Stat5b, which dimerizes and translocates to the nucleus, to bind 
response elements to regulate transcription of GH target genes. The transcription of 
specific genes leading to the production of other peptides like IGF-1. (Rico-Bautista et al., 
2005) 
Although GH signalling through STAT proteins is the primary signaling pathway (Figure 
12).  
The transcription factor STAT5 acts to induce expression of the key growth mediator 
(Waters and Brooks, 2012) 
GH may regulate the phosphorylation of a range of STATs and this may depend on the cell 
type; 
for example, STAT5 is activated by GH in adipocytes but not in adherent epithelial cells. 
(Han et al., 1996) 
 To date, the specific STAT family member(s) involved in mediating GH signaling in 
chondrocytes has focused on STAT5b is, as yet, unknown. It has been shown that both 
GHR and STAT5 are localized to the resting, proliferating and pre-hypertrophic 
chondrocytes, and thus STAT5 phosphorylation in response to GH is likely to occur 
predominantly in these zones. (Gevers et al., 2009) 
Different studies suggest GH actions on chondrocytes have STAT5 independent effects. 
(Sims et al.,2000; Giustina et al., 2008) Interestingly, growth retardation and reduced 
circulating IGF-1 are observed in STAT5b null mice but not STAT5a null mice, suggesting 
that STAT5b may be the important isoform in GH signaling in bones, so STAT5b seem to 
be the crucial mediator of GH-induced IGF-1 transcription. (Herrington et al.,2000) 
In humans, mutations of GHR or STAT5b that result in the inhibition of STAT5b signaling 
but maintain STAT1 and STAT3 and MAPK-ERK signaling result in severe short stature. 
(Kofoed et al.,2003) 
 
Figure 12: Growth hormone signalling pathway 
 
 
 
 
 
 
 
 
 
 
4.4 Negative regulator of GH: Suppressor of Cytokine Signalling-2 (SOCS2) 
 
Cytokine signaling is negatively controlled by a variety of proteins, including protein 
tyrosine phosphatases and the SOCS proteins. There have been eight SOCS molecules 
identified, CIS and SOCS1-7, all of which are involved in negatively regulating cytokine 
signaling. SOCS proteins consist of a conserved C-terminal motif named the SOCS box, a 
central SH2 domain and a variable N-terminal domain. They can bind through their SH2 
domains to phosphorylated tyrosines within the cytokine receptor-JAK complex and inhibit 
JAK signaling and downstream STAT activation. 
Expression of SOCS is normally stimulated by the very cytokines they inhibit, thereby 
creating a negative feedback loop. (Pass et al., 2012) 
SOCS1 and SOCS3 have been shown to inhibit signaling by IL-2, IL-3, IL-4, IL-6, GH, 
prolactin, erythropoietin, IFN- , IFN- , oncostatin M (OSM), thymic stromal 
lymphopoietin (TSLP), thrombopoietin (TPO), thyrotropin and IGF-1. It can directly bind 
phosphorylated JAK proteins via its SH2 domain. (Greenhalgh et al., 2005; Piessevaux et 
al., 2006) 
CIS and SOCS2 can inhibit signaling by IL-2, IL-3, prolactin, erythropoietin, IGF-1 and 
GH and inhibits STAT signaling by interacting with the cytokine receptor to block STAT 
binding sites. (Krebs and Hilton, 2001) 
Inhibition of GH signaling by SOCS1 and 3 is complete whereas SOCS2 and CIS only 
cause partial inhibition and it is difficult to reconcile these actions with the observed 
growth of the transgenic mice. (Lee et al., 2008) 
Clearly, other interactions are important possibly involving the other SOCS proteins. 
It has been proposed that at physiological levels, SOCS2 inhibits GH signalling by 
blocking sites of STAT activation on the GHR, but at higher doses it inhibits signalling of 
other, more potent GH inhibiting SOCS (SOCS1 and 3). (Greenhalgh et al., 2005) 
Expression of SOCS is usually stimulated by the cytokines that they can inhibit, so that 
they create negative feedback loops. GH signalling is inhibited by CIS, SOCS1, SOCS2 
and SOCS3, but this work in chondrocytes will focus on SOCS2. 
Incidentally, these four SOCS proteins (CIS, SOCS1, 2 and 3) are the only ones that have 
been widely studied and it is possible other SOCS family members may also inhibit GH 
signalling. (Inaba et al.,  2005) 
It has been well documented that GH signalling stimulates SOCS2 expression, 
furthermore, it is thought that SOCS2 production is regulated by GH signalling through 
STAT5b. (Vidal et al.,2007) 
This confirms the hypothesis that SOCS2 acts in a negative feedback loop to control and 
regulate GH signalling under physiological conditions. 
The precise mechanism by which SOCS2 regulates GH signalling is unclear.  
There are still many aspects on the actions of SOCS2 that have yet to be investigated. The 
precise mechanism by which SOCS2 alters GH/IGF-I signalling have yet to be fully 
determined as are the resultant cellular events that occur at the growth plate and are 
responsible for normal growth. It is also unclear if SOCS2 mediates the deleterious effects 
of inflammatory cytokines on linear bone growth. 
Moreover it has been shown that SOCS2 and CIS-1 expression are reduced in OA 
chondrocytes compared to healthy chondrocytes. These results indicate a potential positive 
feedback mechanism in OA chondrocytes, with significant implications for OA pathology. 
Further understanding of the role of SOCS proteins in chondrocytes will be needed to 
determine their therapeutic potential for OA. (de Andrès et al., 2011) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5 GH and signalling molecules in normal and OA cartilage 
 
A number of signalling molecules involved in chondrocyte activity, like proliferation or 
differentiation, in growth cartilage were also shown to play a regulative role in OA 
articular cartilage (Table 3). 
 
Table 3: Different signalling factors involved in both chondrocyte differentiation processes 
during endochondral ossification and in osteoarthritis 
 
 
 
Chondrocyte differentiation in growth cartilage is subject to positive and negative control 
elements that interact within a signalling network to regulate the rate and progression of 
the process. (Kronenberg, 2003) 
hormones, such as GH and IGFs, tightly regulate longitudinal bone growth. Local and 
systemic agents control the rate and extent of chondrocyte proliferation and differentiation 
at several checkpoints. This endocrine control enables longitudinal bone growth in healthy 
individuals and leads to increased growth rates and subsequent growth plate closure around 
puberty. GH and IGFs are potent stimulators of longitudinal bone growth, both factors 
stimulate proliferation of resting zone chondrocytes and initiate chondrocyte hypertrophy. 
(Hunziker et al., 1994) 
GH exerts its effects on the growth plate predominantly through stimulation of secretion of 
insulin-like growth factor 1 (IGF1), both by liver cells and by growth plate chondrocytes. 
(Nilsson et al.,2005; Pass et al., 2009) 
Under normal conditions, the cells remain in a resting state and do not undergo 
proliferation or differentiation. In a diseased state, however, some articular chondrocytes 
lose their differentiated phenotype, and activate proliferation and hypertrophic 
differentiation, inducing specific markers. (Tallheden et al., 2005)   
More information were obtained studying small animals, which better reflect human OA 
pathophysiology. 
With regard to the GH/IGF-I axis, however, it was shown in a rat model of OA that 
chronic GH deficiency causes an increased severity of articular cartilage lesions of OA, 
although the IGF-I expression is increased. (Ekenstedt et al., 2006)  
IGF-1 is considered one of the factors responsible for preservation or loss of the articular 
cartilage matrix. It has been shown that this factor enhance chondrocyte proliferation, 
proteoglycan and collagen synthesis by chondrocytes in normal cartilage, also during 
cytokine exposure, and drives most predominating catabolic process in cartilage. 
(Yammani and Loeser, 2012; Claessens, 2011) IGF-1 is also involved in the differentiation 
and hypertrophy of chondrocytes. (Repudi et al., 2013)  
Anabolic IGF-I signaling is antagonized by increased occurrence of IGF-binding proteins, 
which then negatively regulate IGF-I signaling in chondrocytes during OA. (Martel-
Pelletier et al., 1998)  
Cytokines, like IL-1, inhibit cartilage matrix production, stimulate catabolic activity in 
cartilage, and appear to play a role in the development of OA, so IGF-1can inhibit the 
activity of IL-1 and increasing the activity of IGF-1 in cartilage, would be of potential 
benefit in preventing cartilage, degeneration and the progression to OA. (Ekenstedt et al., 
2006) 
Studies have shown that in OA there is a decrease of GH, this could also be due to a 
decrease of circulating hormones, besides data on GH actions on chondrocyte proliferation 
have so far been largely conflicting, some authors show strong proliferative effects of GH 
while others show little or none. (Madsen et al., 1983;  Hutchison et al., 2007) Another 
functions of GH is that it could also increase cartilage metabolism. (Dunn, 2002) 
An another important aspect is that patients with inflammatory conditions can have 
variable levels of GH but generally reduced levels of circulating IGF-1, indicating GH 
resistance. (Wong et al., 2010) 
IL-6, in combination with IL-6 receptor, has been shown to inhibit articular chondrocyte 
differentiation via the JAK/STAT pathway decreasing IGF-1 levels. (Legendre et al., 
2003) 
It is also possible that inflammatory cytokines act on GH signalling but to date little 
knowledge of the effects of inflammatory cytokines on STAT signalling are available on 
chondrocytes. (Dreier, 2010)  
 
4.6 GH in OA treatment 
 
The administration of growth hormone has been well documented to be useful in the 
treatment of statural impairment in Turner syndrome, intrauterine growth restriction, 
chronic renal failure and above all in GH deficiency or insufficiency. (Brooks et al., 2008)  
Therapy with recombinant human GH has also been used in humans with chronic 
inflammatory diseases and has shown variable extent of improvement in growth and even 
disease. (Mauras et al., 2002; Wong et al., 2007) 
Scientists suggested that GH dysfunction was part of OA pathogenesis, but the relationship 
between GH levels and OA is poorly understood. 
Why is it important study GH in OA?  
There are different data demonstrating an important GH role in OA disease. In particular, 
in several  animals studies it has been shown that GH: 
1. Stimulates IGF-1 production and induces chondrocytes proliferation; (Tsukazaki et al., 
1994; Madsen et al., 1983) 
2. Stimulates the extracellular matrix synthesis; (Smith et al., 1975) 
3. Stimulates the formation of bone and cartilage; (Mankin et al., 1978) 
4. Modulates the proliferation and apoptosis of chondrocytes, through the stimulation of 
NF- p65;  
but it has also been demonstrated that in animals it could increase collagen type 10. (Wu et 
al., 2011) 
Several studies using GH in animals have demonstrated that hGH intra-articular 
administration is a potential anabolic treatment for OA. Interestingly some preclinical data 
have suggested that GH has potential regenerative property in the joint. However, the short 
half-life (16 hours) of the native protein in the joints limits its utility as a therapeutic agent, 
but a study has demonstrated that exogenous hGH exhibits longer half-lives in joint than 
native hGH. (Nemirovskiy et al., 2010) 
In a OA rat knees model, it appears that the exogenous GH, for not clear reason, seem to 
exert a more protective function than endogenous GH. 
GH and IGF-1 are required in the adult rat to maintain articular cartilage integrity and a 
deficiency of these proteins leads to OA-like lesions. The age-related reduction in GH and 
IGF-1 levels in humans may therefore contribute to the development of OA. (Ekenstedt et 
al., 2006) 
The effects of GH in human fetal epiphyseal and osteoarthritic chondrocytes not induce 
IGF-1 production even if the basal levels of IGF-1 and GH are higher in the synovial fluid 
and serum of OA patients. (Fernandez-Cancio et al., 2009; Dore et al., 1995; Denko and 
Malemud, 2005; Denko et al., 1996) 
Private practices in USA already use hGH as an OA intra-articular therapy to regenerate 
articular cartilage, and a study of 66 patients with advanced OA of the knee treated with 
GH shown excellent results, in fact the patients did not need total knee arthroplasty. (Dunn, 
2012) 
moreover, a clinical X-ray study document that OA patients treated with GH shown 
signifying articular cartilage repair. (Hauser, 2009) 
5. Aim 
 
Osteoarthritis (OA) is the most common joint disease, and is characterized by progressive 
loss of articular cartilage, subchondral bone sclerosis, osteophyte formation, synovial 
membrane changes, and an increase in synovial fluid with decreased viscosity and 
lubrication properties. Mechanical, biochemical, and genetic factors are all involved in 
pathogenesis of OA. 
Chondrocytes are considered active protagonists in cartilage damage: while in healthy 
cartilage these cells exert a strict control over the turnover of the extracellular matrix 
(ECM). In OA cartilage catabolic and anabolic processes are enhanced with the overall 
result of the loss of functional tissue and ECM degradation, so articular cartilage lesions, 
with their inherent limited healing potential, are hard to treat and remain a challenging 
problem. 
In this context, it is trying to develop new drugs that allow to treat OA reducing pain, 
maintaining joint function and preventing disability. 
Intra-articular injection into osteoarthritic joints may play an important role in the 
therapeutic plan.  
Injection should be contemplated as complementary to the overall treatment plan-never as 
the only component of therapy. At this time, no targeted treatments for osteoarthritis have 
been developed. Therefore, preclinical and clinical research studies using other 
pharmacologic agents that might provide additional benefit are currently underway. 
In this context, the pharmaceutical industry Fidia Farmaceutici SpA (Abano Terme, PD, 
Italy) has developed a new chemically modified hyaluronic acid (HYADD®4-G) and 
commissioned a study aimed to evaluate the effects in vitro on human osteoarthritic 
chondrocytes of the interaction between different concentration of hGH alone or in 
combination with HYADD®4-G, to define their effect for developing a new drug therapy 
for intra-articular OA treatment. 
To reach this aim, the study was divided in the following sections: 
1) Analysis of growth hormone receptor and of hyaluronan receptor on normal and 
OA chondrocytes; 
2) Analysis of hGH and HYADD®4-G effect on chondrocytes: cellular migration, 
morphology, cell viability and metabolic activity of OA treated chondrocytes; 
3) Analysis of the effect of hGH and HYADD®4-G on CD44, GHR, chondrocytic 
markers, release of IGF-1, FGF-2 and IL-6; 
4) Analysis of factors involved in the GH mechanism of action (SOCS2). 
6. Materials and Methods 
 
 
6.1 Patient characteristics 
 
Cartilage tissue was obtained from the femoral condyles of OA patients (n=8) undergoing 
total knee replacement with a  Kellegren/Lawrence grade 3-4 (Kellgren and Lawrence, 
1957) (Table 4).   
 
Table. 4 OA patients characteristics 
Patients Age Sex BMI Disease duration 
(year) 
Oral drugs 
#1 46 F 25,6 1  NSAIMs* 
#2 55 F 23,2 2  
#3 56 F 23,4 10 NSAIMs* 
#4 65 M 26 5  
#5 67 F 27,5 2 NSAIMs* 
#6 68 F 30,8 8 NSAIMs* 
#7 70 F 33,4 2 NSAIMs* 
#8 78 F 24,8 4 NSAIMs* 
Mean 63  27 7  
SD ±9,98  ±3,60 ±7,54   
*Nonsteroidal anti-inflammatory drugs 
 
 
 
 
 
Normal cartilage biopsies (n=3) were obtained at autopsy from donating organ subjects 
(Table 5).  
 
Table. 5 Normal donor characteristics 
Patients Age Sex BMI 
#1 20 F 26 
#2 28 M 23 
#3 16 M 19 
Mean 21,3  22,7 
SD ±6,1  ±3,5 
 
 
The study was approved by the local ethics committee and all patients provided their 
informed consent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2 Immunoistochemical analysis  
 
Cartilage tissue from normal subjects and OA patients were fixed in a freshly prepared 9:1 
mixture of B5 solution (mercuric-chloride containing fixative)/40% formaldehyde at room 
temperature for 2 hours, decalcified in 0.1M ethylenediaminetetraacetic acid (EDTA), 
dehydrated and embedded in paraffin.  
Embedded-samples were cut at 5µm using a microtome. Slides were then deparaffined in 
xylene and hydrated through a series of alcohol steps (from ethanol 100° to 70°). 
Slides were washed in distilled water for 5 minutes, then the sections were re-equilibrated 
in Tris-buffered saline (TBS: NaCl, Trizma, HCl 37%)  containing 1% bovine serum 
albumin (BSA) for 10 minutes at room temperature. 
The slides were incubated with monoclonal anti-human GHR (Santa Cruz Biothechnology, 
Santa Cruz, CA, USA) diluted 1:200 or monoclonal anti-human CD44 (R&D Systems, 
McKinley Place NE, Minneapolis, U.S.A) diluted 1:50 , in TBS containing 0.1% BSA 
overnight at 4°C, and then sequentially incubated with multilinker biotinilated secondary 
antibody (Biocare Medical, Concord, CA, USA) and alkaline phosphatase-conjugated 
streptavidin (Biocare Medical) for 20 minutes at room temperature. 
The reactions were developed using fast red substrate (Biocare), counterstained with 
hematoxylin and mounted in glycerol gel. The sections were evaluated with a bright field 
microscope (Nikon Instruments Europe BV, Amstelveen, the Netherlands). Negative and 
isotype-matched controls sections were performed either by omitting the primary 
antibodies or using an isotype-matched control. 
 
 
6.3 Cellular culture 
 
6.3.1 Chondrocytes isolation 
 
Chondrocytes were isolated following a standardized procedure. (Grigolo et al., 2002) 
Briefly, the cartilaginous fragments were weighed and then placed in culture medium 
Dulbecco's Modified Eagle's Medium (DMEM, Sigma-Aldrich) containing penicillin / 
streptomycin (100 U/ml, Gibco), gentamycin (0.05 mg/ml, Eurobio), and 10% of fetal 
bovine serum (FBS, Gibco), (defined as COMPLETE DMEM). The fragments were 
incubated in a solution with protease (13,25 U/ml, Sigma-Aldrich) to digest the cartilage 
matrix for 60 minutes at 37°C.  
After incubation, the samples were washed twice in COMPLETE DMEM for 5 minutes 
each. 
Subsequently, the cartilaginous fragments were further cut with a scalpel to reduce the 
tissue to a consistency of homogenate, and transferred to a sterile bottle containing DMEM 
with collagenase type II (545 U/ml, Sigma-Aldrich). The homogenate was transferred in a 
bottle containing a magnetic stirrer and incubated in a water-bath at 37 °C until complete 
digestion of cartilaginous fragments, for not longer than 2 hours. 
After incubation, cells suspension was filtered sequentially using three different cells 
strainer (100 m, 70 m and 40 m), and the effects of collagenase enzymatic action was 
blocked adding FBS. 
These steps are performed to remove tissue residues and possible cellular aggregates in 
order to obtain a cell population as homogeneous as possible.  
The sample was centrifuged for 7 minutes at 677 x g and the resulting pellet resuspended 
in an appropriate volume of COMPLETE DMEM.  
The cells were then counted using the vital dye Eosin in Neubauer counting chamber. 
Cells isolated were seeded (passage 0, p0) in COMPLETE DMEM at the density of 
1,8x106, in flasks having an area of 150 cm2 and incubated in a humidified atmosphere 
(37°C, 5% CO2).  
The cultured cells were checked daily and the culture medium was changed twice a week. 
After reaching confluence, cells were washed with a buffer solution of Hank supplemented 
with NaHCO3 and glucose. Chondrocytes were detached from the flask using a trypsin 
solution at 0,05% EDTA at 37°C for 6-8 minutes.  
Trypsin activity was blocked adding FBS and cells suspension was transferred into sterile 
tubes and centrifuged for 5 minutes at 410 x g.  
The pellet was resuspended in culture medium for chondrocytes (COMPLETE DMEM), 
counted and use for the experiments. 
 
6.3.2 Synoviocytes isolation  
 
As control cells we isolated human synoviocytes from synovial tissue following 
standardized procedure. (Haubeck, 1995) 
Briefly, synovial tissue was dissected from underlying connective tissue and minced 
fragments (approximately 1×1 mm) were transferred into a petri 3003 and cultured in 12 
ml of Optimem-1 (Life Technologies Italia Srl, San Giuliano Milanese, Italy) 
supplemented with 15% FBS, 50 µg/ml of gentamicin (complete medium). After 7 10 
days of culture, tissue fragments were removed and synovial cells outgrown from the 
synovial tissue were mantained in culture. Cells from the second passage were used for the 
experiments. 
 
6.4 Experimental culture conditions 
 
Chondrocytes were seeded in monolayers at two-cell densities (12.500 cells/cm2 and 
24.000 cells/cm2) and cultured in COMPLETE DMEM medium  at 37°C in 5% CO2. 
Twenty-four hours later, the medium was removed and chondrocytes were treated with: 1) 
fresh medium (basal condition); 2) human Growth Hormone (hGH, kindly provided by 
Fidia Farmaceutici s.p.a., Abano Terme, PD, Italy) at different concentrations (0.01 
 3) hyaluronan amide derivative (HYADD®4-G 
kindly provided by FIDIA Farmaceutici, Abano Terme, PD,  USA patent N.7863256) at 1 
mg/ml or 4) HYADD®4-G in combination with all different concentrations of hGH.  
HYADD®4-G stock solution (8 mg/ml) was diluted 1:2 (4 mg/ml) the day before and let 
gently rotating overnight at 37°C, to ensure a homogenous and fluid solution. This 
procedure is necessary due to the high viscosity of this solution. 
24 hours later the solution was diluted 1:2 (2 mg/ml) and then mixed (50.50) with the 
different concentrations of hGH to have a final concentration of HYADD®4-G at 1 mg/ml.  
Cell cultures were analyzed at different time points (24, 48, 72 hours and 7 days) for: 
morphology, viability, cell proliferation, metabolic activity, cell migration, CD44 and 
GHR expression, molecular biology analysis, protein assays evaluation, and analysis of 
GH and HA pathways.  
 
6.5 Cellular morphology 
 
Cellular morphology was analyzed using toluidine blue, a metachromatic dye that stains 
the nucleus blue and the cytoplasm light blue/purple. 
Chondrocytes were fixed, after 7 days of culture, in 10% formaldehyde for 15 minutes at 
room temperature. Slides were washed twice and incubated with 1% solution of toluidine 
blue for 10 seconds, and then washed 4 times with distilled water under agitation for 5 
minutes each. 
 
6.6 Cellular viability  
 
LIVE & DEAD viability kit (Molecular ProbesTM Invitrogen, Paisley, UK) was used to 
evaluate chondrocyte viability. 
Chondrocytes were seeded in 24-well plates at the highest cell concentration, 48 hours and 
7 days later, cells were washed three times in 1 ml of buffer solution (D-PBS: 200 mg/l 
KCl + 8 g/l NaCl + 1.15 g/l Na2HPO4 + 200 mg/l KH2PO4) and then incubated with 1 ml 
of ethidium/calcein solution (4µM EthD/ 2 µM calcein AM) at 37°C, in 5%CO2 for 45 
minutes. The cells were washed twice with D-PBS and the cell fluorescence evaluated by 
fluorescence microscopy.  
Cells were visualised using 2 filters, one at 495 nm to evidence live cells (stained by green 
fluorescent calcein) and one at 510 nm to evidence dead cells (stained by red fluorescent 
ethidium). 
 
 
 
 
 
 
 
 
6.7 Cellular metabolic activity 
 
To evaluate cellular metabolic activity, the chondrocytes (48 x 103 cells) were seeded in a 
24-well plates at all the conditions previously described. At each time point the 
chondrocytes were washed three times and incubated with 10% Alamar Blue® solution 
(AbD Serotec, Oxford, UK) in a humidified atmosphere at 37 °C in 5% CO2. After 6 h, 
100 µl of medium was collected and transferred to 96-well plates and absorbance read at 
570 nm and 600 nm. (Figure 13) 
The percentage of Alamar Blue® reduction was calculated according to the 
instructions:   
 
Where: O1 = molar extinction coefficient of oxidized alamarBlue (Blue) at 570nm (80586) 
O2 = molar extinction coefficient of oxidized alamarBlue at 600nm (117216) 
R1 = molar extinction coefficient of reduced alamarBlue (Red) at 570nm (155677) 
R2 = molar extinction coefficient  of reduced alamarBlue at 600nm (14652) 
A1 = absorbance of test wells at 570nm 
A2 = absorbance of test wells at 600nm 
N1 = absorbance of negative control well (media plus alamarBlue but no cells) at 570nm 
N2 = absorbance of negative control well (media plus alamarBlue but no cells) at 600nm 
 
 
 
Figure 13:  AlamarBlue® assay converts resazurin to resorufin 
 
 
 
6.8 Cellular migration  
 
To evaluate the migration of cells, chondrocytes and control synoviocytes were seeded in a 
24-well plates (48 x 103 cells). 
After 24 hours in each well was done a scratch in the center using a tip and then the cells 
were washed 2 times with medium. 
Basal cells and cells treated with HYADD®4-G 1mg/ml were exposed to normoxia  (at 
37°C in 20% O2) and in hypoxia (at37°C in 5% O2). After 24 hours medium was eliminate, 
cells were fixed with 10% formaldehyde for 15 minutes at room temperature, stained with 
Toluidine Blue and observed under a bright field microscope (Nikon Instruments Europe 
BV, Amstelveen, the Netherlands). 
 
6.9 Immunocychemical analysis 
 
Cells were plated in eight-well chamber slides at a density of 10.000 cells/well. The day 
after cells were treated with hGH or HYADD®4-G as previously describe and after 48 
hours the chamber slides were washed twice with PBS and fixed in 4% paraformaldehyde 
(PFA) for 20 minutes at room temperature. Then slides were incubated with TBS + 1% 
BSA to block non-specific staining for 10 minutes. 
Cells were then incubated with the following antibodies: monoclonal anti-human GHR 
(Santa Cruz Biothechnology, Santa Cruz, CA, USA) diluted 1:200, or anti-human CD44 
diluted 1:20 (clone NIH44 ibridoma obtained from ATCC, Manassas, VA, USA), or anti-
human SOCS2  diluted 1:150 (Cell Signaling Technology, Inc., Danvers, MA USA). All 
the primary antibody were diluted  in TBS containing 0.1% BSA and incubated at 4°C 
over night. Slides were washed 3 times with TBS and then incubated with multilinker 
biotinilated secondary antibody (Biocare Medical, Concord, CA, USA) and alkaline 
phosphatase-conjugated streptavidin (Biocare Medical) at room temperature for 
30 minutes.  
The reactions were developed using fast red substrate (Biocare), counterstained with 
hematoxylin and mounted in glycerol gel. The sections were evaluated with a bright field 
microscope. Negative and isotype-matched controls were performed either by omitting the 
primary antibodies or using an isotype-matched control. 
6.10 Molecular biology analysis 
 
6.10.1 RNA extraction 
 
At the experimental times (24h, 48h and 72h), all wells were lysed by adding 1 ml of 
reagent EUROGOLD RNA per well (Euroclone). 
Total RNA was extracted from the cell lysate by the addition of chloroform, which allows 
to separate the RNA from the cellular components and interfering substances. After 
centrifugation al 12.000 x g two phases were obtained: 
upper); 
lower). 
The aqueous phase was collected, treated with isopropanol and and centrifuged at 12.000 x 
g to allow the RNA precipitation. The RNA pellet was then washed with 75% ethanol. 
Subsequently, the pellet was treated with DNase I (DNA-free DNase Kit, Ambion) to 
remove 
any DNA contamination. 
The extracted RNA was analyzed by UV spectrophotometer (NanoDrop) at 260 and 280 
nm. Absorbance at 260 nm was measured to determinate RNA concentration and 260/280 
nm ratio to evaluate RNA purity. 
 
6.10.2 Reverse transcription 
 
Reverse transcription was performed using "VILO SuperScript cDNA Synthesis Kit" 
(Invitrogen). Each sample (0,5 µg) was diluted in a reaction mixture (20 µl final volume) 
consisting of: 
- 5X VILO Reaction Mix (4 uL); 
- 10X SuperScript Enzime Mix (2 uL); 
- RNase-free H2O to a total volume of 20 µl.  
Reverse transcription was performed as follow: 10 minutes at 25°C, 60 minutes at 42°C 
and 5 minutes at 85°C. 
At the end, all the samples were diluted with H2O to obtain a concentration of 10 ng/µl and 
 
 
 
6.10.3 Real Time PCR 
 
Primers for PCR amplification were generated from GenBank sequences using the Primer3 
Software (Rozen and Skaletsky, 2000). BLASTN searches were conducted on all 
oligonucleotide sequences to ensure pairing specificity. The housekeeping gene ribosomal 
protein subunit 9 (RPS9) was used as an endogenous control to normalize for intersample 
variations in the amount of total RNA.  (Table 6). 
 
Table. 6 Oligonucleotides sequences 
TARGET 
GENE 
PRIMERS PRODUCT 
SIZE (bp) 
GENE BANK 
ACCESSION No. 
RPS9 Forward: 
GATTACATCCTGGGCCTGAA 
Reverse: 
ATGAAGGACGGGATGTTCAC 
161 NM_001013 
COL1A1 Forward: 
CCTGGATGCCATCAAAGTCT 
Reverse: 
CGCCATACTCGAACTGGAAT 
170 NM_000088 
 
COL2A1 Forward: 
GACAATCTGGCTCCCAAC      
Reverse: 
ACAGTCTTGCCCCACTTAC 
257 NM_001844 
NM_033150 
COL10A1 Forward: 
TGCTGCCACAAATACCCTTT 
Reverse: 
GTGGACCAGGAGTACCTTGC 
192 NM_000493 
 
SOCS2 Forward: 
CTCGCATTCAGACTACCTAC 
Reverse: CTGTCCGCTTATCCTTG 
191 NM_001270471.1 
 
 
 
Real time PCR was run in a LightCycler Instrument (Roche Molecular Biochemicals, 
Mannheim, Germany) using the SYBR Premix Ex Taq (TaKaRa Biomedicals, Tokyo, 
Japan) with the following protocol:  activation of Taq DNA polymerase at 95°C for 10 sec, 
followed by 45 cycles of 94°C for 5 sec and  60°C for 20 sec. The increase in PCR product 
was monitored for each amplification cycle by measuring the increase in fluorescence 
caused by the binding of SYBR Green I Dye to dsDNA.  The crossing point (CT) values 
(i.e. the cycle number at which the detected fluorescence exceeds the threshold value) were 
determined for each sample and specificity of the amplicons was confirmed by melting 
curve analysis.  
For each target gene mRNA levels were calculated from the CT values using the 
quantitative relative method (2- Ct) and expressed as percentage of the housekeeping gene. 
 
 
 
 
 
 
 
 
 
 
6.11 Soluble factors analysis 
 
6.11.1 Multiplex system 
 
Soluble factors were evaluated by "Milliplex® MAP Kit" (Millipore, St. Charles, Missouri, 
U.S.A). 
The principle of this assay is based on color-coded magnetic beads, which covalently binds 
the biomarker of interest. Bead coloration is achieved by utilizing different concentrations 
of red and infrared fluorophore dyes to create 100 uniquely-colored bead sets. Considering 
that these bead sets contain a unique color / fluorophore signature, they can then be 
combined within the same assay well. 
As shown in Figure 14 each analyte analyzed bind to the captured antibody. Then a 
secondary biotinylated antibody specific for a different epitope of the markers of interest is 
used as detection antibody, and finally the complex Streptavidin-Phycoerythrin (SA-PE) 
conjugate is responsible for the fluorescence signal. 
 
 
 
 
Figure 14: Assay Steps in Detecting Fluorescent Intensities 
 
This system was used to evaluate the expression profile of the cytokines IL-6 and FGF-2 in 
the supernatant of chondrocytes.  
Specifically, the plate containing the filter in the bottom is prewet adding 200 µl of Assay 
Buffer and then the liquid was removed by vacuum. Diluted standards and sample (50 µl) 
were added to each well and then were added the mixed beads (25 µl). The plate was 
incubated under rotation on a plate shaker for 1 hour at room temperature. Fluid was then 
removed gently by vacuum and the plate washed twice with wash buffer. Biotinylated 
secondary antibody was added to wells and plate incubated under rotation on a plate shaker 
for 1 hour at room temperature. Plates were each washed twice and and Streptavidin-PE 
added to each well and incubated for 5 minutes. The plate was read with the fluorimeter. In 
particular, the suspension was sucked in a test instrument (Bio-Plex Array System), which 
uses a system of microfluidics to align the microspheres in a single row in a column of 
liquid, which are intercepted by two laser beams with wavelengths appropriate. The first 
illuminates the fluorophores inside the ball (color code) and the second excite the 
fluorochrome bound to the 'complex on the surface of the microsphere. Subsequently, an 
advanced optical system captures fluorescence signals. 
 
6.11.2 Test ELISA : Enzyme-linked immunosorbent assays 
 
The most popular application for immunological detection is the Enzyme-Linked 
Immunosorbent Assay (Quantikine® ELISA, R&D Systems, McKinley Place NE, 
Minneapolis, U.S.A).  
This assay employs the quantitative sandwich enzyme immunoassay technique. This 
system was used to quantized IGF-1 in supernatants. 
The plate is pre-coated with a monoclonal antibody anti-IGF-1. Standards, control and 
samples are added into the well and incubated for 2 hours at 4°C. 
The plate was washed to remove unbound substances, and enzyme-linked polyclonal 
antibody, specific for a different epitopes, IGF-1 was added to the wells and incubated for 
1 hour at 4°C. The plate was washed, a substrate solution was added to each well and 
incubated for 30 minutes at room temperature. The colour in the well should change from 
blue to yellow in proportion to the amount of IGF-1 bound. The colour development was 
stopped adding 50 µl of stop solution in each well and the intensity of the colour was 
measured by a spectrophotometer. The absorbance was read at 450 nm and 540 nm. 
(Figure 15) 
 
 
 
Figure 15: Quantikine ELISA Assay Principle 
 
6.12 Intracellular proteins analysis by Western Blotting 
 
6.12.1 Protein extraction 
 
Primary chondrocytes were washed in PBS to remove excess medium and cells were 
scraped in presence of 120 µl lysis buffer containing inhibitor cocktail mix: 2 µl/ml 
phenylmethanesulfonylfluoride (PMSF), 5 µl/ml protease inhibitor cocktail mix (PIC),  2 
µl/ml sodium fluoride (NaF), 4µl/ml sodium orthovanadate and 991 µl Tris-HCl-NaCl-
Nonidet P-40-SDS (Bio-Rad Laboratories) 
Samples were stored for 15 minutes in ice and then centrifuged 10.000 rpm for 15 minutes 
to recover the protein samples. Samples were then stored at -20°C. 
Protein content was determined using a  (Thermo 
scientific, Rockford, USA), which is a colorimetric assay for detecting protein 
concentration. Serial dilutions of BSA was used as standard ranging from 2 to 0.025 
mg/ml. 
96-well plate was used for the assay, and each well contained 10 l sample/standard and 
200 µl of the working reagent (ratio 50:1, reagent A : reagent B). The plate was incubated 
37°C for 30 minutes, then protein levels were measured by absorbance at 562 nm. 
The protein concentration of each sample was calculated from the standard curve. 
 
6.12.2 Western Blot 
 
was loaded in the wells of NuPAGE® Novex® 
precast 4-12% polyacrylamide gel (Invitrogen, Life Technologies) which was subsequently 
transferred onto polyvinylidene fluoride 
membranes by a dry electroblotting method using IBlot® Gel Transfer Device (Invitrogen, 
Life Technologies).  
The membrane was blocked with  0,25% BSA in TBS for 10 minutes at room 
temperaturean then incubated with polyclonal anti-human SOCS2  diluted 1:200 (Cell 
Signaling Technology, Inc., Danvers, MA USA) in 0,25% BSA (Fraction V) at 4°C 
overnight.  Sequentially incubated with an anti-mouse IgG HRP (211-032-171,115-035-
174, Jackson ImmunoResearch, West Grove, PA,  USA). Signal detection was revealed 
using Amersham ECL Select kit (RPN2235, GE Healthcare Italia, Milan, Italy) and 
acquired through KODAK Image Station 4000R Digital Imaging System (Kodak, 
Rochester, NY, USA). and Carestream Molecular Imaging Software 5.0. (Carestream 
Health, Inc.). -actin (Sigma) was used as loading controls. 
 
 
6.13 Statistical analysis 
 
The experimental design considered for each patient the following conditions: 1. two 
different treatments (hGH and HYADD®4-G), six different  concentrations (0, 0.01, 0.1, 1, 
10, 100 nd their combinations at four different time points (24h, 48h, 72h and 7 
days). Therefore, the statistical units included in the analysis were 384 (8 patients x 2 
treatments x 6 concentrations x 4 time points ) or less (depending on marker analyzed) and 
the statistician selected the multivariate analysis to increase the power of the study. 
Specifically was used General Linear model (GLM) for repeated measures with the 
following parameters: the age of the patients as covariates and treatments (hGH and 
HYADD®4-G), concentrations (0, 0.01, 0.1, 1, 10, 100 and cell numbers and their 
combinations as fixed effects. This statistical model permit to calculate also the correlation 
among two parameters (e.g. age and collagen type 2 etc.) considering more than one 
independent variable (e.g. the time course). P-value <0.05 was considered statistically 
significant. All graphs were performed using the program GraphPad Prism and data 
express as mean and 95% confidence interval or as mean ± SD. 
7. RESULTS 
 
7.1  GHR and CD44 expression on cartilage biopsies and isolated chondrocytes 
 
We firstly analyzed the receptors of growth hormone (GHR) and hyaluronic acid (CD44) 
at protein level by immunohistochemistry on cartilage biopsies from healthy subjects and 
OA patients. 
As shown in Figure 16A-B, GHR was positive in chondrocyte clusters of OA cartilage and 
only in a few cells in normal cartilage.  
 
 
Figure 16A-B: GHR expression on cartilage biopsies. A: Immunohistochemical analysis 
of GHR on healthy cartilage (a) and OA (b). Isotype-matched negative control (c). Bars: a, 
b, c, = 200µm. Inset bars = 10 µm. B: Data of the immunocytochemical are expressed as 
mean ± SD. Significant differences are highlighted by the asterisk *. 
 
 
CD44 was positive in  few cells both in OA and in normal cartilage. (Figure 17) 
 
 
 
 
 
 
Figure 17: CD44 expression on cartilage biopsies. Immunohistochemical analysis of 
CD44 on healthy cartilage (a) and OA (b). Isotype-matched negative control (c). Bars: a, b, 
c, = 200µm. Inset bars = 10 µm.  
 
 
 
 
 
 
 
Subsequently we analyzed these receptors in OA isolated chondrocytes by 
immunocytochemical analysis. As shown in Figure 18 GHR and CD44 were both 
expressed in OA isolated chondrocytes. 
 
 
 
 
 
Figure 18: GHR and CD44 expression on OA isolated chondrocytes. 
Immunocytochemical evaluation of GHR (a) and CD44 (b) on isolated chondrocytes, 
isotype-matched negative control (c). Bars: a, b, c = 100µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.2 HYADD®4-G effect on chondrocytes 
 
We noted that at 24 hours HYADD®4-G, added to the wells, forms a solid plug that 
covered all the area of the well and does not permit the analysis of cell morphology by 
contrast microscope. HYADD®4-G became more soluble at 7 days and by contrast 
microscope was possible to observe adherent cells (Figure 19).  
 
 
 
 
 
 
Figure 19: Evaluation of HYADD®4-G characteristic in culture treated with HYADD®4-G 
for 24 hours and 7 days. Bars = 100µm. 
 
 
 
 
 
 
 
Therefore, we decided  to assess if HYADD®4-G was able to mimic in vivo joint 
environment creating an hypoxic condition for the cells. A scratch assay was performed on 
chondrocytes and control migrating cells (synovial fibroblast) cells cultured under 
normoxic (20%O2)  and hypoxic (5%O2) conditions were also tested. The Figure 20A 
shows representative images of chondrocytes and synoviocytes under normoxic conditions, 
while in Figure 20B are shown the cells under hypoxic condition. 
 Figure 20: Scrath assay on chondrocytes and fibroblast-like synoviocytes treated with or 
without HYADD®4-G A: under normoxic condition (20% O2) B: under hypoxic condition 
(5% O2). Bars = 100µm 
In normoxia, after 24 h from the scratch, chondrocytes do not migrate to fill the wound 
both in basal conditions and in presence of HYADD®4-G, while fibroblast-like 
synoviocytes in basal condition start to migrate to cover the scratch, instead with 
HYADD®4-G did not migrate. By contrast in hypoxia condition, after 24 hours from the 
scratch, in basal condition and treated with HYADD®4-G, both chondrocytes and 
fibroblast-like synoviocytes did not migrate to cover the scratch confirming that 
HYADD®4-G contribute to maintain hypoxic condition. 
7.3 Morphology and viability of chondrocytes treated with hGH and 
HYADD®4-G 
 
Morphology was evaluated by Toluidine Blue staining and viability by live and dead assay, 
respectively. In basal conditions Toluidine Blue stained chondrocytes showed a rounded, 
polygonal morphology, whereas after hGH treatment we observed an increase in mitosis 
and cells with rounded shape independently from the different hGH concentrations tested 
(Figure 21).  
 
Figure 21: Morphological characteristics of OA chondrocytes treated with hGH and 
HYADD®4-G alone or in combination. Morphological characteristics of isolated OA 
chondrocytes stained with Toluidine Blue in basal conditions (Basal), treated with hGH 
1 g/ml (+hGH), HYADD®4-G 1mg/ml (+HYADD®4-G) or their combination 
(HYADD®4-G +hGH). Bars = 50µm.
Conversely, HYADD®4-G-treated chondrocytes still showed mitosis but their shape 
appeared more as fibroblast-like cells.  
The viability test confirmed that the chondrocytes were viable at all time points analyzed. 
In particular, the different hGH concentrations used with or without HYADD®4-G did not 
induce cell death from 48 hours until 7 days (Figure 22). 
Figure 22: Analysis of chondrocyte viability in basal conditions (Basal), after treatment 
 HYADD®4-G 1mg/ml (+HYADD®4-G) or their combination 
(HYADD®4-G +hGH), using the live and dead test at 48 hours (A) and at 7 days (B). 
Calcein-AM positive cells (green) are alive; propidium iodide cells (red) are dead. Bars = 
100µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.4 Evaluation of chondrocyte metabolic activity  
 
We investigated chondrocyte metabolic activity using Alamar Blue assay. In basal 
conditions chondrocyte metabolic activity showed the same values and trend as those of 
hGH (independently of the concentration used) treated cells, while this activity was 
decreased by the treatment with HYADD®4-G both on basal and hGH treated cells (Figure 
23A). GLM repeated measures statistical analysis showed  that the metabolic activity, 
independently from the treatment used, proportionally decreased with the increasing age of 
-0.17) (Figure 23B). Moreover, the statistical analysis confirmed that 
none of the concentrations of hGH (0.01- used both individually or in 
combination with HYADD®4-G affected the metabolic activity. However, as shown in 
Figure 23C HYADD®4-G treatment significantly decreased this activity at all the time 
points analyzed (p<0.05).  
 
 
 
Figure 23: Analysis of chondrocytes metabolic activity treated with hGH or HYADD®4-
G. A. Evaluation of chondrocytes metabolic activity at different time points (24h, 48h, 72h 
and 7 days) after treatment with hGH (0.01- HYADD®4-G (1mg/ml) alone or 
in combination. Data are expressed as absorbance (mean and 95% confidence interval). B. 
GLM statistical analysis showed that the  metabolic activity was proportionally decreased 
with the increasing the age of the patients -0.17). Age ranges: <60 years, 60-70 years, 
>70 years). C. GLM statistical analysis showed significant differences, highlighted by 
asterisks (^ for 24h, * for 48h, o for 72h and + for day 7), between treatments (hGH versus 
HYADD®4-G), independently by the concentrations used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.5 Effect of hGH and HYADD®4-G on GHR and CD44  
 
Immunocytochemical analysis was performed to evaluate GHR and hyaluronan receptor 
CD44 on treated chondrocytes. GHR, was not modulated by different treatment performed 
(data not shown). 
As shown in Figure 24A-B, in basal conditions CD44 was positive on a low percentage of 
chondrocytes and the treatments with hGH 1  or HYADD®4-G increased the number 
of positive cells after 24h. Interestingly, the combination of HYADD®4-G with hGH 
induced a synergic increase of positive cells.  
 
 
 
 
 
Figure 24: Analysis of CD44 receptor in chondrocytes treated with hGH or with 
HYADD®4G±hGH. A. Immunocytochemical evaluation of CD44 on isolated 
chondrocytes (Basal), after treatment with hGH 1µg/ml (+hGH) or HYADD®4-G or 
HYADD®4-G + hGH 1µg/ml. Bars = 100µm. B. Data of the immunocytochemical are 
expressed as mean ± SD. Significant differences in all condition tested (Basal, +hGH, + 
HYADD®4-G, HYADD®4-G +hGH) are highlighted by the asterisk *.   
 
 
7.6 Effects of hGH and HAD on chondrocyte markers  
 
Collagen type 2 a specific positive marker of chondrocyte and collagen type 1 and 10 
markers of chondrocyte fibrosis and hypertrophy, respectively, were evaluated in basal 
condition, after treatment with hGH (0.01-100 HYADD®4-G with or 
without all hGH concentrations.  Collagen type 2, collagen type 1 and collagen type 10 
(Figure 25) expression was unaffected by none of the concentrations of hGH-treatments 
alone or in combination with HYADD®4-G at all time points tested.  
 
 
 
 
Figure 25: Analysis of chondrocyte markers expression over time. Collagen type 2, 
collagen 
type 1, collagen type 10 expression was evaluated at different time points (24h, 48h 
and72h) in basal condition and after treatment with hGH (0.01-100 HYADD®4-G 
(1 mg/ml) alone or in combination. Data are expressed as % RPS9 (mean and 95% 
confidence interval).  
 
 
GLM repeated measure statistical analysis evidenced that the expression level of all these 
markers, independently from the treatment used (hGH or HYADD®4-G), progressively 
-0.4 , -80, - 0.003, respectively) 
(Figure 26).  
 
Figure 26: Chondrocyte markers expression in patients with different age and treatments. 
GLM statistical analysis showed that collagen type 2, collagen type 1 and collagen type 10 
expression was proportionally decreased with the increasing the age of the patients (  = -
0.4, -80, -0.003, respectively). Age ranges (<60 years, 60-70 years, >70 years). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Both the treatments applied (hGH or HYADD®4-G) showed a significant decrease 
(p<0.01) from 24h to 72h of the expression of all markers analyzed (Figure 27). Moreover, 
HYADD®4-G treatment significantly (p<0.05) decreased collagen type 2 and 1 expression 
and partially affected collagen type 10. In particular, HYADD®4-G significantly decreased 
collagen type 10 only at 72h.  
 
 
 
 
 
 
 
 
Figure 27: Chondrocyte markers expression in patients with different age and treatments.  
Comparison between treatments (hGH versus HYADD®4-G) for collagen type 2, collagen 
type 1 and collagen type 10 expression, showed significant differences, highlighted by 
asterisks (^ for 24h, * for 48h ando for 72h), between hGH versus HYADD®4-G, 
independently by the concentrations used.  
 
 
7.7 Release of IGF-1, FGF-2 and IL6 by treated chondrocytes 
 
Human OA chondrocytes did not release IGF-1 and FGF-2 at any of the time points 
analyzed or conditions tested. IL6 release was significantly induced only by hGH 100 
µg/ml from 48 h to 7 days (Figure 28).  
 
 
 
 
Figure 28: IL6 release of chondrocytes treated with hGH or HYADD®4-G alone or in 
combination. IL6 release was evaluated at different time points (48h, 72h and 7 days) on 
chondrocytes in basal condition and treated with hGH (0.01-100 µg/ml) alone or combined 
with HAD (1mg/ml). Data are expressed as pg/ml (mean and 95% confidence interval). 
 
 
 
 
 
 
 
 
 
 
 
Conversely, when hGH (independently of the concentration used) was combined with 
HYADD®4-G, IL6 release was significantly down-modulated GLM statistical analysis 
indicated that the release of IL6 significantly increased from 48 h to 7 days independently 
from the treatment applied (hGH or HYADD®4-G), but it was not age-related (Figure 29). 
 
Figure 29: A. IL6 release of chondrocytes treated with hGH or HYADD®4-G alone or in 
combination. GLM statistical analysis showed significant differences, highlighted by 
asterisks (* for 48h, o for 72h and + for day 7), between treatments (hGH versus 
HYADD®4-G), independently by the concentrations used. B. IL6 release in patients with 
different age and treatments. GLM statistical analysis showed that IL6 was not age-related 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.8 Evaluation of SOCS2 
 
The expression of SOCS2, a negative regulator of GH signaling, was also analyzed on 
basal and treated chondrocytes. SOCS2 expression showed the same levels and trend in 
basal condition, after treatment with hGH (0.01-100 HYADD®4-G, with or 
without all  hGH concentrations (Figure 30A). GLM statistical analysis showed that 
SOCS2 expression, independently from the treatment (hGH or HYADD®4-G) used 
proportionally decreased with the increasing age of the patient -0.25) (Figure 30B). 
SOCS2 expression was not induced by any concentrations of hGH alone or in combination 
with HYADD®4-G. However, as shown in Figure 30C, statistical analysis evidenced that 
HYADD®4-G treatment significantly induced SOCS2 expression at all time points tested.  
Western blotting for SOCS2 was unsuccessful since HYADD®4-G, that has an high 
viscosity, interferes with the protein analysis (data not shown). Therefore, we decided to 
analyze the protein expression of SOCS2 with the immunocytochemical analysis. 
As shown in Figure 30D-E, we found that HYADD®4-G induced a significant 
translocation of the protein into the nucleus compared to basal condition.
 
Figure 30: Analysis of SOCS2 in chondrocytes treated with hGH or HYADD®4-G alone 
or in combination. A. SOCS2 expression was evaluated on chondrocytes at different time 
points (24h, 48h and 72h) in basal condition and after treatment with hGH (0.01-
or HYADD®4-G (1 mg/ml) alone or in combination. Data are expressed as %RPS9 (mean 
and 95% confidence interval). B. GLM statistical analysis showed that SOCS2 expression 
was -0.25).   Age 
ranges (<60 years, 60-70 years, >70 years). C. GLM statistical analysis showed significant 
differences, highlighted by asterisks (^ for 24h, * for 48h and o for 72h), between 
treatments (hGH versus HYADD®4-G), independently by the concentrations used. D. 
Immunocytochemical analysis of SOCS2 on OA isolated chondrocytes. Representative 
pictures of basal (a), HAD treated condition (b) and isotype-matched negative controls (c). 
Bars: a, b, c = 50µm. E. Immunocytochemical quantification of SOCS2 on isolated 
chondrocytes (Basal), after treatment with hGH 1µg/ml or HYADD®4-G (1mg/ml)  or 
HYADD®4-G + hGH 1µg/ml. Data are expressed as mean ± SD. Significant differences in 
all condition tested (Basal, +hGH, + HYADD®4-G, HYADD®4-G +hGH) are highlighted 
by the asterisk *. 
 
 
 
8. DISCUSSION 
 
Available drugs for treating OA mainly contribute to reducing pain, but only in part 
counteract the progression of the disease. Therefore, much effort is aimed at finding new 
drugs with structure-modifying activity to test if their potential and efficacy was influenced  
by the age of OA patients. (Grishko et al., 2009; Fukui et al., 2014; Yatabe et al., 2009; 
Peng et al., 2010; Kataoka et al., 2013) Based on recent data showing the positive effects 
of GH on cartilage in an animal model (Tsukazaki et al., 1994; Wu et al., 2011; Alvarez-
Garcia et al., 2012; Hunziker et al., 1994), and knowing the efficacy of HA in preventing 
OA (Gomis et al., 2009; Mainil-Varlet et al., 2013) we evaluated the potentiality of hGH 
and HAD on human OA chondrocytes of patients ranging from 46 to 78 years old.  
First, we found that GHR was positive in only a few chondrocytes of healthy cartilage and 
it was highly positive on OA cartilage and isolated OA chondrocytes, thus suggesting its 
potential involvement in articular cartilage maturation and pathological processes. 
Its expression becomes quiescent in mature articular cartilage and is re-expressed in the 
pathological state of OA, thus indicating a different involvement in cellular processes both 
in normal and OA cartilage as found for vascular endothelial growth factor receptor. 
(Lingaraj et al., 2010) When isolated OA chondrocytes were treated with hGH, we showed 
that some of them changed their morphology from a spindle to a round shape, instead, 
HYADD®4-G treatment showed a fibroblast-like shape. However, hGH and HYADD®4-G 
treatment for 7 days induced the death of only a few cells, thus indicating that even at high 
hGH concentrations (100 µg/ml) the cell viability remained very high.  
The metabolic activity of chondrocytes did not reveal any effect of different hGH 
concentrations tested on OA chondrocytes, whereas this activity was significantly reduced 
by HYADD®4-G alone and in combination with hGH at all the time points considered, 
thus confirming that HYADD®4-G interfere in some way with GH or modulate its 
pathways. Our data are not in line with a previous paper (Brun et al., 2012) that reported 
HAD-induced metabolic activity; this difference was probably due to either the low 
number of OA patients analyzed (three) or to different in vitro tests and conditions as 
demonstrated by others. (Li et al., 2013; Loeser, 2013)  
Hyaluronan CD44 receptor is expressed in lower amount in normal cartilage and is 
increased in OA mainly in chondrocyte clusters. (Ostergaard et al., 1997) It has been 
shown that hGH from 0.01 µg/ml induces the hyaluronan receptor CD44 on human arterial 
smooth muscle cells (Schultz  et al., 2005), as we also found on human OA chondrocytes, 
thus suggesting that a combination of hGH with HYADD®4-G increased CD44 receptor, 
that as reported  is essential for HYADD®4-G effects, so contributing to potentiate the 
effects of HYADD®4-G.  
Interestigly, we demonstrate that HYADD®4-G not stimulates cellular migration as occur 
in hypoxic conditions tested suggesting that HYADD®4-G is probably able to mimic an 
ideal environment for chondrocytes creating an hypoxic condition close to joint in vivo. 
The other aspect that we evaluated concerns the analysis of the major chondrocyte 
markers. We found that neither collagen type 2, nor collagen type 1 and 10 were affected 
by the different hGH concentrations tested. It has been shown on chondrocytes from rats 
that GH at low concentrations induce collagen type 10 expression (Wu et al., 2011), 
highlighting a differential effect with respect to human OA chondrocytes. When hGH was 
combined with HYADD®4-G did not affect the expression of typical chondrocytic marker 
(collagen type 2), or of typical fibrotic (collagen type 1) and hypertrophic (collagen type 
10) chondrocytic markers, as previously reported using the same HYADD®4-G 
concentration. (Smith et al., 2013).  
In line with another report (Dore et al., 1995) we found that hGH, alone or in combination 
with HYADD®4-G, was unable, at all different concentrations tested, to induce the release 
of IGF-1 or FGF2 by chondrocytes, thus suggesting that STATs signaling, strictly 
dependent on SOCS2, was not triggered by GH in these cells. IGF-1 in basal conditions is 
not released by human OA chondrocytes or human epiphyseal chondrocytes (Fernandez-
Cancio et al., 2009), thus indicating that GH and IGF-1 do not act in concert as usually 
occurs in animal proliferating chondrocytes (Hunziker et al., 1994). In fact, although IGF-1 
and GH are released in the synovial fluid and serum of OA patients (Denko et al., 1996), 
our data indicate that it is not GH that trigger GH release. 
Our data also evidenced that OA chondrocytes after hGH treatment at  high concentration 
(100 µg/ml)induce the  release of IL6 , whereas when in combination with HYADD®4-G 
its production was significantly reduced. These data were in line with a recent study (Smith 
et al., 2013) that showed that HYADD®4-G alone was already able to reduce dose-
dependently IL6 expression. 
To define the role of these two molecules better, we focused our attention on the 
suppressor of cytokine signaling SOCS2 a negative regulator of GH signaling. It was 
shown that SOCS2 mRNA was reduced approximately eight fold in OA chondrocytes 
compared to controls (de Andres et al., 2011). Our data show that SOCS2 mRNA 
expression was not induced by all the hGH concentrations tested, suggesting that 
GH/STAT/IGF-1 signaling pathway is blocked and explaining the absence of IGF-1 
release by treated chondrocytes. Conversely, our data highlighted for the first time that 
HYADD®4-G treatment was able to induce SOCS2 expression at all the time points tested, 
and increased nuclear protein translocation, thus indicating a direct effect of HYADD®4-G 
on a negative regulator of hGH. This finding confirms that HYADD®4-G modulates 
SOCS2 and might also explain the reduced metabolic activity found after  treating human 
chondrocytes with HYADD®4-G.  
Together, all these findings, evidence that hGH and HYADD®4-G combination is 
biologically effective on OA chondrocytes since these factors act on the respective 
receptors so balancing their effects. 
Moreover, our data demonstrate a proportional decrease of some of the parameters tested 
(metabolic activity, collagen type 1, 2, 10 and SOCS2 expression) was found with the 
increasing the age of the patients, thus supporting an age-dependent response to the targets 
analyzed. According to our data, this age-dependent response was previously reported also 
for other chondrocytes parameters such as matrix synthesis (Bolton et al., 1999), reduced 
responsiveness to growth factors (van der Kraan et al., 2010). 
These data also suggests the importance to define an age-range for OA clinical treatments, 
where the effects of intra-articular treatment could be more efficacious for its use in 
patients. Our data indicated that, even though,  the treatment tested were independent to the 
age, suggesting that their use could be advantageous for OA treatment independently than 
the age of the patients.  
In conclusion, our data show that hGH was unable to induce human OA chondrocyte 
metabolic activity, IL6 or IGF1 or FGF2 release or chondrocytic markers but increased the 
expression of CD44. The effects of hGH on human chondrocytes were down-modulated 
when used in combination with HYADD®4-G, which significantly induced SOCS2 
expression and translocation into the nucleus. However, these treatments did not affect the 
response of the OA chondrocytes demonstrating that the cellular response was  age-
independent and suggesting that their efficacy was not related to the age of the OA 
patients. 
However, further experiments are necessary to evaluate the pathways involved in this 
regulation process and focusing on chondrocytes in 3D culture systems using a defined  
GH and HYADD®4-G concentration; to confirm the efficacy of this treatment on the other 
tissues that compose the knee joint (e.g. synovium and bone). 
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